prompt,completion,enhanced_prompt,enhanced_completion,reasoning_trace,context,original_context,persona_injection
Summarize the main finding of this biomedical study in one sentence.,T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells.,"### Task
Summarize the main finding of the biomedical study provided below into exactly one sentence.

### Input Data
**Title:** Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.
**Abstract:** T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness while exhibiting clonal enrichment, initially preserved memory-associated progenitor states, delayed exhaustion, and transiently activated telomerase delaying telomere attrition. Early transcriptomic responses show coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function while restricting differentiation-associated signaling programs, mirroring long-term functional outcomes. These findings demonstrate that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.

### Constraints
- **Length:** The output must be a single sentence.
- **Focus:** Capture the primary discovery regarding the mechanism and outcome described in the abstract.
- **Accuracy:** Ensure all technical terms (e.g., CAR-T, CAREp, PLGA) are used correctly as presented in the source text.","Programmable DNA-scaffolded PLGA microparticles termed CAREp, which display CAR-targeting antigens and CD28-costimulatory antibodies, enable sustainable ex vivo expansion of human CAR-T cells without genetic rewiring by utilizing nanoscale ligand organization to synchronize acute signaling with durable proliferative and metabolic states, thereby preserving effector function and mitochondrial fitness while delaying exhaustion and telomere attrition.","Okay, I need to summarize this biomedical study into exactly one sentence. Let me break down what's happening here.

The study is about CAREp — these are programmable DNA-scaffolded PLGA microparticles that display CAR-targeting antigens and CD28-costimulatory antibodies. The core problem they're addressing is that CAR-T cell expansion ex vivo has been limited, and existing strategies require genetic rewiring. So the innovation is a non-genetic, external approach to stimulate expansion.

What's the main finding? Let me think about what's truly central here. The key discovery seems to be that these CAREp particles can sustain massive expansion (over 100 days, up to 1018-fold) across different CAR constructs, and the mechanism is about nanoscale ligand organization synchronizing acute signaling with durable proliferative and metabolic states.

I need to capture both the mechanism and the outcome. The mechanism is the nanoscale ligand organization on these particles. The outcomes are: sustained expansion without genetic modification, preserved effector function, maintained mitochondrial fitness, delayed exhaustion, delayed telomere attrition.

Let me think about what to include and what to leave out. The transcriptomic details are supporting evidence, not the main finding. The comparison to Dynabeads and tumor cells shows superiority but isn't the core discovery. The clonal enrichment is a detail.

The sentence needs to mention: CAREp, what they are (DNA-scaffolded PLGA microparticles with CAR-targeting antigens and CD28 antibodies), the key outcome (sustainable CAR-T expansion without genetic rewiring), the mechanism (nanoscale ligand organization synchronizing signaling with proliferative/metabolic states), and the functional benefits (effector function, mitochondrial fitness, delayed exhaustion, telomere maintenance).

Let me draft this... I need to be careful about length — one sentence but comprehensive. I should use the technical terms correctly as they appear in the abstract.

The abstract's concluding sentence is essentially the thesis: ""nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states."" I should build around that.

Let me construct the sentence to flow logically: what the particles are → what they achieve → how they work (mechanism) → what functional outcomes result. That structure captures the discovery comprehensively in one sentence.","Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness while exhibiting clonal enrichment, initially preserved memory-associated progenitor states, delayed exhaustion, and transiently activated telomerase delaying telomere attrition. Early transcriptomic responses show coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function while restricting differentiation-associated signaling programs, mirroring long-term functional outcomes. These findings demonstrate that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.","Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness while exhibiting clonal enrichment, initially preserved memory-associated progenitor states, delayed exhaustion, and transiently activated telomerase delaying telomere attrition. Early transcriptomic responses show coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function while restricting differentiation-associated signaling programs, mirroring long-term functional outcomes. These findings demonstrate that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.","# Constraints
The question you must answer is from a science domain. You are a senior immunologist and CAR-T cell therapy researcher with 15 years of experience in synthetic biology and translational oncology. Based in a leading Boston biotech hub, you specialize in T-cell signaling pathways and ex vivo expansion techniques. Your expertise in nanoscale ligand organization makes you the ideal authority to distill complex biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear.","# Task
Summarize the main finding of the biomedical study provided below into exactly one sentence.

# Study Content
**Title:** Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer.

**Abstract:** Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN18.2 expression by immunohistochemistry in paired tumor samples from 155 patients with advanced GC/EGJC was retrospectively evaluated before and after systemic therapy. CLDN18.2-positive was defined as ≥75% of viable tumor cells exhibiting moderate-to-strong (2+ or 3+) membranous staining. Among all patients, 54 (34.84%) were CLDN18.2-positive. Following treatment, the proportion of CLDN18.2-positive patients increased significantly to 61 (39.35%) (p < .001). Among patients who were CLDN18.2-negative at baseline, 57 (56.44%) showed increased expression after treatment, including 22 (21.78%) who converted to positive status. In contrast, among those CLDN18.2-positive at baseline, expression decreased in 35 patients (64.81%), with 15 (27.78%) converting to negative status (p < .001). Among patients receiving chemotherapy alone (n = 25), 1 (4.00%) converted to negative and 5 (20.00%) converted to positive, whereas among those receiving chemotherapy combined with immunotherapy (n = 130), 14 (10.77%) converted to negative and 17 (13.08%) converted to positive (p = .45). A total of 131 patients (84.52%) demonstrated changes in CLDN18.2 expression following therapy, encompassing both conversions acros","Systemic therapy for gastric and esophagogastric junction adenocarcinoma induces highly dynamic changes in Claudin 18.2 expression, with over 84% of patients demonstrating altered expression levels and significant bidirectional conversion between positive and negative status regardless of the treatment regimen, resulting in an overall increase in the proportion of CLDN18.2-positive tumors.","Let me carefully read through this study abstract and figure out what the main finding is.

Okay, so the study is looking at Claudin 18.2 (CLDN18.2) expression in gastric and esophagogastric junction adenocarcinoma — specifically how it changes dynamically during systemic therapy. They evaluated paired tumor samples from 155 patients before and after treatment using immunohistochemistry.

Let me parse the key results:

1. At baseline, 54 patients (34.84%) were CLDN18.2-positive.
2. After treatment, this increased significantly to 61 (39.35%), p < .001.
3. Among baseline-negative patients, 56.44% showed increased expression, with 21.78% converting to positive.
4. Among baseline-positive patients, 64.81% showed decreased expression, with 27.78% converting to negative.
5. The treatment type (chemo alone vs. chemo + immunotherapy) didn't significantly differ in conversion rates (p = .45).
6. 84.52% of patients demonstrated changes in CLDN18.2 expression.

So what's the main finding here? The key takeaway is that CLDN18.2 expression is highly dynamic — it changes in the vast majority of patients after systemic therapy. There's bidirectional conversion: some go from negative to positive, some from positive to negative. The net effect is actually an increase in the proportion of CLDN18.2-positive tumors. And importantly, these changes happen regardless of whether patients got chemotherapy alone or chemotherapy combined with immunotherapy.

Now I need to distill this into exactly one sentence. Let me think about what's most essential:

- The dynamic nature of expression changes (84.52% showing changes)
- Bidirectional conversion (both directions observed)
- Significant changes (p < .001)
- Net increase in positive proportion
- Treatment regimen didn't matter (p = .45)

Let me try drafting:

""Systemic therapy for gastric and esophagogastric junction adenocarcinoma induces highly dynamic changes in Claudin 18.2 expression, with over 84% of patients demonstrating altered expression levels and significant bidirectional conversion between positive and negative status regardless of the treatment regimen, resulting in an overall increase in the proportion of CLDN18.2-positive tumors.""

Let me check this — it's one sentence. It captures the main finding: the dynamism, the bidirectional nature, the treatment-independence, and the net effect. I think this works well. It synthesizes the key points without getting lost in the specific percentages, which would make the sentence unwieldy.

Actually, let me reconsider whether I'm including too much detail. The prompt asks for the ""main finding."" The main finding could be argued to be simply that CLDN18.2 expression is highly dynamic after therapy with bidirectional conversions. But the net increase in positive proportion and the treatment-independence are important contextual findings that complete the picture. I'll keep them in.

One more check: is the sentence grammatically correct and readable? Yes, I think so. It's a single compound sentence that flows logically from the intervention (systemic therapy) to the primary observation (dynamic changes) to the specific patterns (bidirectional conversion, treatment-independence) to the net outcome (increased positive proportion).

I'm satisfied with this summary.","Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN18.2 expression by immunohistochemistry in paired tumor samples from 155 patients with advanced GC/EGJC was retrospectively evaluated before and after systemic therapy. CLDN18.2-positive was defined as ≥75% of viable tumor cells exhibiting moderate-to-strong (2+ or 3+) membranous staining. Among all patients, 54 (34.84%) were CLDN18.2-positive. Following treatment, the proportion of CLDN18.2-positive patients increased significantly to 61 (39.35%) (p < .001). Among patients who were CLDN18.2-negative at baseline, 57 (56.44%) showed increased expression after treatment, including 22 (21.78%) who converted to positive status. In contrast, among those CLDN18.2-positive at baseline, expression decreased in 35 patients (64.81%), with 15 (27.78%) converting to negative status (p < .001). Among patients receiving chemotherapy alone (n = 25), 1 (4.00%) converted to negative and 5 (20.00%) converted to positive, whereas among those receiving chemotherapy combined with immunotherapy (n = 130), 14 (10.77%) converted to negative and 17 (13.08%) converted to positive (p = .45). A total of 131 patients (84.52%) demonstrated changes in CLDN18.2 expression following therapy, encompassing both conversions acros","Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN18.2 expression by immunohistochemistry in paired tumor samples from 155 patients with advanced GC/EGJC was retrospectively evaluated before and after systemic therapy. CLDN18.2-positive was defined as ≥75% of viable tumor cells exhibiting moderate-to-strong (2+ or 3+) membranous staining. Among all patients, 54 (34.84%) were CLDN18.2-positive. Following treatment, the proportion of CLDN18.2-positive patients increased significantly to 61 (39.35%) (p < .001). Among patients who were CLDN18.2-negative at baseline, 57 (56.44%) showed increased expression after treatment, including 22 (21.78%) who converted to positive status. In contrast, among those CLDN18.2-positive at baseline, expression decreased in 35 patients (64.81%), with 15 (27.78%) converting to negative status (p < .001). Among patients receiving chemotherapy alone (n = 25), 1 (4.00%) converted to negative and 5 (20.00%) converted to positive, whereas among those receiving chemotherapy combined with immunotherapy (n = 130), 14 (10.77%) converted to negative and 17 (13.08%) converted to positive (p = .45). A total of 131 patients (84.52%) demonstrated changes in CLDN18.2 expression following therapy, encompassing both conversions acros","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and translational researcher specializing in gastric cancer biomarkers. With 15 years of clinical experience and a focus on immunohistochemistry, you expertly interpret dynamic protein expression changes to guide systemic therapy decisions for patients worldwide. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | Carcinoma, Non-Small-Cell Lung | Female | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal | Male | Lung Neoplasms | Aged | Middle Aged | Chemoradiotherapy | Neoplasm Staging | Antineoplastic Combined Chemotherapy Protocols | Adult | Progression-Free Survival | Consolidation Chemotherapy","Extract and list the Medical Subject Headings (MeSH) terms that index the provided study.

**Input Data:**
Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespe","Based on the provided title and abstract, the following Medical Subject Headings (MeSH) terms are appropriate for indexing this study:

* Carcinoma, Non-Small-Cell Lung
* Lung Neoplasms
* Canakinumab
* Durvalumab
* Antibodies, Monoclonal, Humanized
* Immune Checkpoint Inhibitors
* Chemoradiotherapy
* Combined Modality Therapy
* Interleukin-1 beta
* Neoplasm Staging
* Clinical Trials, Phase I as Topic
* Clinical Trials, Phase II as Topic
* Progression-Free Survival
* Treatment Outcome
* Humans","The user wants me to extract MeSH terms from a study. Let me break down what's in this abstract.

The study is the CHORUS trial - a phase I/II trial testing canakinumab (anti-IL-1β monoclonal antibody) with chemoradiation and durvalumab (anti-PD-L1) consolidation in unresectable stage III NSCLC.

Let me work through the key elements:

**Disease/Condition:**
- ""unresectable stage III non-small cell lung cancer"" → *Carcinoma, Non-Small-Cell Lung* is the primary disease MeSH term. I should also include *Lung Neoplasms* as the broader parent term, which is standard indexing practice.
- ""stage III"" → *Neoplasm Staging* applies here since staging is relevant to the study design.

**Drugs/Interventions:**
- Canakinumab - this is a specific monoclonal antibody targeting IL-1β. It has its own MeSH term: *Canakinumab*. I should also include *Interleukin-1 beta* since the mechanism (anti-IL-1β) is central to the study rationale.
- Durvalumab - this is an anti-PD-L1 immune checkpoint inhibitor. It has its own MeSH term: *Durvalumab*. I should also include *Immune Checkpoint Inhibitors* as the broader class.
- Both are monoclonal antibodies - canakinumab is fully human, durvalumab is humanized. *Antibodies, Monoclonal, Humanized* captures this.

**Treatment Modalities:**
- ""chemoradiation"" / ""chemoradiotherapy"" → *Chemoradiotherapy* and *Combined Modality Therapy* both apply. The study explicitly combines multiple treatment modalities (canakinumab + chemoradiation + durvalumab), so both terms are warranted.

**Study Design:**
- ""phase I/II trial"" → *Clinical Trials, Phase I as Topic* and *Clinical Trials, Phase II as Topic*
- ""open-label, non-randomized, single-arm"" → These are design details but the phase I/II designation is the most important MeSH-indexable aspect.
- ""NCT04905316"" - this is just the registration number, not a MeSH term.

**Endpoints/Outcomes:**
- ""progression-free survival"" → *Progression-Free Survival* is a MeSH term.
- ""overall survival, objective response rate, and safety"" → *Treatment Outcome* covers these outcome measures.

**Population:**
- Human study (patients enrolled) → *Humans* should always be included.

Let me compile the full list and make sure I haven't missed anything important. I think that covers the major indexable concepts: disease, drugs, treatment modalities, study design, endpoints, and population.","Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespe","Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespe","# Constraints
The question you must answer is from a medical domain. You are a senior medical librarian and oncology research specialist with 15 years of experience in clinical trial indexing. You possess deep expertise in MeSH terminology, non-small cell lung cancer treatments, and immunotherapy protocols. Your precise knowledge ensures accurate mapping of complex study data to standardized medical subject headings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL).","# Task: Biomedical Study Summary

Generate a single-sentence summary of the main finding from the study provided below.

## Constraints
- **Length**: Exactly one sentence.
- **Focus**: Capture the primary conclusion regarding the efficacy and safety of the proposed therapy.
- **Tone**: Professional and scientific.

## Study Data
**Title**: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells.

**Abstract**: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD28 CAR T cells match anti‑CD7 CAR T cells in vitro and in vivo, but cause markedly less lymphodepletion, largely sparing CD8 T cells and NK cells while preferentially depleting CD4 T cells, particularly TH2 and TH17 subsets. These findings establish CD28 as an actionable target for CAR T cell therapy of T cell malignancies.","This study establishes CD28 as a viable target for CAR T-cell therapy in T-lineage malignancies, demonstrating that CRISPR-engineered anti-CD28 CAR T cells achieve anti-tumor efficacy comparable to anti-CD7 CAR T cells while offering a superior safety profile characterized by markedly reduced lymphodepletion and the preservation of CD8 T and NK cell populations.","Okay, I need to write a single-sentence summary of this study. Let me break down what's happening here.

The study is about T-cell malignancies — specifically T-ALL and nodal T-follicular helper cell lymphomas. The problem is that current CD7-directed CAR T cells, while effective initially, cause severe T cell aplasia and face CD7-negative immune escape. So they need a better target.

They identified CD28 as overexpressed on T-ALL blasts and uniformly upregulated in nTFHL subtypes. That's the target rationale.

The engineering approach: CRISPR/Cas9 knockout of CD28 to prevent fratricide — because the CAR T cells themselves would express CD28 and kill each other. Smart approach. Then they generate anti-CD28 CAR T cells and test them.

Key findings on efficacy: these anti-CD28 CAR T cells match anti-CD7 CAR T cells both in vitro and in vivo. So non-inferior efficacy.

Key findings on safety: markedly less lymphodepletion compared to anti-CD7. They spare CD8 T cells and NK cells, though they do preferentially deplete CD4 T cells (TH2 and TH17 subsets). So the safety profile is better but not perfect — there's still some CD4 depletion.

The conclusion: CD28 is an actionable target for CAR T cell therapy of T cell malignancies.

Now I need to distill this into exactly one sentence that captures both efficacy and safety. The sentence needs to be professional and scientific.

Let me think about what's essential: the target (CD28), the approach (CRISPR-engineered anti-CD28 CAR T cells), the efficacy (comparable to anti-CD7), and the safety advantage (less lymphodepletion, preservation of CD8 T cells and NK cells). I should probably mention the disease context — T-lineage malignancies.

Let me draft something: ""This study establishes CD28 as a viable target for CAR T-cell therapy in T-lineage malignancies, demonstrating that CRISPR-engineered anti-CD28 CAR T cells achieve anti-tumor efficacy comparable to anti-CD7 CAR T cells while offering a superior safety profile characterized by markedly reduced lymphodepletion and the preservation of CD8 T and NK cell populations.""

Let me check — is this one sentence? Yes. Does it capture efficacy? Yes, ""comparable to anti-CD7."" Does it capture safety? Yes, ""reduced lymphodepletion"" and ""preservation of CD8 T and NK cells."" Is it professional and scientific? Yes.

I could mention the CD4 depletion, but that might make the sentence too long and dilute the main finding. The primary message is that CD28 is a viable target with comparable efficacy and better safety. I think leaving out the CD4 depletion detail is the right call for a single-sentence summary — the headline finding is the improved safety profile relative to CD7, and the CD4 detail is a nuance.

I'm satisfied with this formulation. It's precise, balanced, and captures the core conclusion.","Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD28 CAR T cells match anti‑CD7 CAR T cells in vitro and in vivo, but cause markedly less lymphodepletion, largely sparing CD8 T cells and NK cells while preferentially depleting CD4 T cells, particularly TH2 and TH17 subsets. These findings establish CD28 as an actionable target for CAR T cell therapy of T cell malignancies.","Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD28 CAR T cells match anti‑CD7 CAR T cells in vitro and in vivo, but cause markedly less lymphodepletion, largely sparing CD8 T cells and NK cells while preferentially depleting CD4 T cells, particularly TH2 and TH17 subsets. These findings establish CD28 as an actionable target for CAR T cell therapy of T cell malignancies.","# Constraints
The question you must answer is from a science domain. You are a senior translational immunologist and hematologist-oncologist specializing in CAR T-cell therapies for T-lineage malignancies. With over 15 years of experience in clinical trials and molecular engineering, you possess deep expertise in CD28 targeting and CRISPR applications. Your background bridges bench research and bedside application, making you the ideal authority to distill complex biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality.","You are an expert biomedical researcher. Summarize the main finding of the study provided below into a single, concise sentence.

### Definitions
- **HA-GVHD**: Hyperacute Graft-Versus-Host Disease, a fulminant form of acute GVHD occurring before neutrophil engraftment.
- **HLA**: Human Leukocyte Antigen.

### Input Text
Title: Hyperacute Graft-Versus-Host Disease. | Abstract: Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality. While incidence of HA-GVHD appears to be decreasing owing to in vivo or ex vivo T-cell depletion strategies, it still contributes with life-threatening side effects in the setting of human leukocyte antigen (HLA) mismatch or T-cell replete grafts with insufficient immune prophylaxis. Clinically, HA-GVHD presents almost always with severe skin involvement accompanied by fever, rash, diarrhea, and hepatic dysfunction. Differential diagnosis includes engraftment syndrome, adverse drug reactions, immunogenic skin reactions, and infectious exanthems. Therapeutic approaches mirror those prescribed for post-transplant acute GVHD, centered on high-dose systemic corticosteroids. Although there is no consensus on managing corticosteroid-refractory cases, ruxolitinib could be considered the therapy of choice based on data from post-engraftment GVHD. Further studies are needed to assess effectiveness of novel agents in corticosteroid-refractory HA-GVHD. The main purpose of this review is to summarize available literature on pathophysiology, incidence, risk factors, differential diagnosis, and treatment considerations for HA-GVHD. Knowledg

### Constraints
- Output exactly one sentence.
- Focus strictly on the primary finding or conclusion of the study.","Hyperacute graft-versus-host disease is a fulminant, high-mortality complication occurring before neutrophil engraftment that is primarily managed with high-dose systemic corticosteroids, with ruxolitinib emerging as a potential therapy for refractory cases requiring further investigation.","Okay, let me carefully read through this prompt. I need to summarize the main finding of a study about HA-GVHD into a single, concise sentence.

Let me break down what the abstract is telling me:

1. HA-GVHD is a fulminant form of acute GVHD that occurs early after allogeneic HCT, before neutrophil engraftment
2. It's associated with increased non-relapse mortality
3. Incidence is decreasing due to T-cell depletion strategies, but it remains a problem in HLA-mismatched or T-cell replete grafts with insufficient prophylaxis
4. Clinical presentation: severe skin involvement, fever, rash, diarrhea, hepatic dysfunction
5. Treatment mirrors post-transplant acute GVHD — high-dose systemic corticosteroids are central
6. For corticosteroid-refractory cases, ruxolitinib could be considered based on post-engraftment GVHD data
7. Further studies needed on novel agents for refractory HA-GVHD
8. The review's purpose is to summarize pathophysiology, incidence, risk factors, differential diagnosis, and treatment

Now, what's the ""main finding"" here? This is a review article, so the ""finding"" is really the synthesis of current knowledge. Let me think about what the key takeaways are:

- HA-GVHD is a serious, early complication with high mortality risk
- It's managed primarily with corticosteroids
- Ruxolitinib is emerging as a potential option for refractory cases
- More research is needed

The constraint says to focus on the ""primary finding or conclusion."" Given this is a review, the main conclusion seems to be about the current state of management — corticosteroids are the backbone, ruxolitinib is emerging for refractory cases, and more studies are needed.

Let me also consider: should I mention the decreasing incidence due to T-cell depletion? That's an important point, but it's more of a background observation than the main finding. The treatment paradigm seems to be the central message.

Let me draft a sentence:

""Hyperacute graft-versus-host disease is a fulminant, high-mortality complication occurring before neutrophil engraftment that is primarily managed with high-dose systemic corticosteroids, with ruxolitinib emerging as a potential therapy for refractory cases requiring further investigation.""

Let me check this against the constraints:
- One sentence? Yes.
- Captures the main finding? I think so — it covers the nature of the disease, the primary treatment, the emerging therapy, and the need for more research.
- Concise? Reasonably so.

Could I make it better? Let me consider whether I'm missing anything critical. The abstract emphasizes the life-threatening nature, the clinical presentation, the differential diagnosis... but for a single-sentence summary, I think the disease characterization plus treatment approach is the right focus.

Actually, let me reconsider — should I mention that incidence is decreasing? That's a notable finding. But the sentence is already getting long, and the treatment paradigm feels more central to the study's purpose and conclusion.

I think my draft is solid. It captures the essence: what HA-GVHD is, how it's treated, and what's emerging. That feels like the main finding of this review.

""Hyperacute graft-versus-host disease is a fulminant, high-mortality complication occurring before neutrophil engraftment that is primarily managed with high-dose systemic corticosteroids, with ruxolitinib emerging as a potential therapy for refractory cases requiring further investigation.""

Yes, I'm satisfied with this. It's one sentence, it's concise, and it captures the primary finding about HA-GVHD's nature and management.","Title: Hyperacute Graft-Versus-Host Disease. | Abstract: Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality. While incidence of HA-GVHD appears to be decreasing owing to in vivo or ex vivo T-cell depletion strategies, it still contributes with life-threatening side effects in the setting of human leukocyte antigen (HLA) mismatch or T-cell replete grafts with insufficient immune prophylaxis. Clinically, HA-GVHD presents almost always with severe skin involvement accompanied by fever, rash, diarrhea, and hepatic dysfunction. Differential diagnosis includes engraftment syndrome, adverse drug reactions, immunogenic skin reactions, and infectious exanthems. Therapeutic approaches mirror those prescribed for post-transplant acute GVHD, centered on high-dose systemic corticosteroids. Although there is no consensus on managing corticosteroid-refractory cases, ruxolitinib could be considered the therapy of choice based on data from post-engraftment GVHD. Further studies are needed to assess effectiveness of novel agents in corticosteroid-refractory HA-GVHD. The main purpose of this review is to summarize available literature on pathophysiology, incidence, risk factors, differential diagnosis, and treatment considerations for HA-GVHD. Knowledg","Title: Hyperacute Graft-Versus-Host Disease. | Abstract: Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality. While incidence of HA-GVHD appears to be decreasing owing to in vivo or ex vivo T-cell depletion strategies, it still contributes with life-threatening side effects in the setting of human leukocyte antigen (HLA) mismatch or T-cell replete grafts with insufficient immune prophylaxis. Clinically, HA-GVHD presents almost always with severe skin involvement accompanied by fever, rash, diarrhea, and hepatic dysfunction. Differential diagnosis includes engraftment syndrome, adverse drug reactions, immunogenic skin reactions, and infectious exanthems. Therapeutic approaches mirror those prescribed for post-transplant acute GVHD, centered on high-dose systemic corticosteroids. Although there is no consensus on managing corticosteroid-refractory cases, ruxolitinib could be considered the therapy of choice based on data from post-engraftment GVHD. Further studies are needed to assess effectiveness of novel agents in corticosteroid-refractory HA-GVHD. The main purpose of this review is to summarize available literature on pathophysiology, incidence, risk factors, differential diagnosis, and treatment considerations for HA-GVHD. Knowledg","# Constraints
The question you must answer is from a medical domain. You are a senior hematologist-oncologist specializing in allogeneic stem cell transplantation, with over 15 years of clinical and research experience in graft-versus-host disease. Based at a leading academic medical center, you routinely manage hyperacute GVHD cases and contribute to consensus guidelines. Your expertise bridges cutting-edge immunology and practical therapeutic strategies for complex post-transplant complications. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | T-Lymphocytes, Regulatory | Histones | Colorectal Neoplasms | Glycerol | Animals | Tumor Microenvironment | Forkhead Transcription Factors | Liver Neoplasms | Mice | Feedback, Physiological","Identify and list the Medical Subject Headings (MeSH) terms that index the study described below. MeSH terms are a controlled vocabulary thesaurus used for indexing articles in PubMed.

Study Details:
Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.
Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to","Based on the provided study title and abstract, the following Medical Subject Headings (MeSH) terms are appropriate for indexing:

**Primary MeSH Terms:**
*   **Colorectal Neoplasms** (The primary cancer type studied)
*   **Neoplasm Metastasis** (Focus on the spread to the liver)
*   **Liver Neoplasms, Secondary** (The target organ of metastasis)
*   **T-Lymphocytes, Regulatory** (The specific CD177+GK+ Treg cell subset analyzed)
*   **Tumor Microenvironment** (The focus on nutritional and spatial differences)
*   **Histones** (Specifically regarding H4K5 lactylation)
*   **Protein Processing, Post-Translational** (Encompassing histone lactylation)
*   **Lactates** (The metabolic byproduct driving the feedback loop)
*   **Glycerol** (The metabolic link in the immunosuppressive activity)
*   **Macrophages** (The interacting immunosuppressive cells)
*   **Immunosuppression** (The functional outcome of the cellular interactions)
*   **CD177 Antigen** (A marker for the identified Treg subset)

**Methodological MeSH Terms:**
*   **Single-Cell Analysis** (Used for identifying the distinct Treg subset)
*   **Transcriptome** (Used for spatial and single-cell expression profiling)

**Suggested Supplementary Terms (Qualifiers/Subheadings):**
*   **Colorectal Neoplasms / metabolism**
*   **T-Lymphocytes, Regulatory / physiology**
*   **Histones / metabolism**","Alright, I need to identify MeSH terms for this study. Let me carefully read through the title and abstract.

Title: ""Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.""

Key concepts I'm picking up here:
- Histone H4K5 lactylation — this is a post-translational modification of histones
- Feedback loop — some kind of regulatory mechanism
- Glycerol — a metabolic component
- Immunosuppressive activity — functional immune modulation
- T regulatory cells (Tregs) — specific immune cell type
- Tumor-associated — cancer context

Now the abstract:

""Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver.""

So we're dealing with:
- Neoplasm metastasis — definitely a MeSH term
- Colorectal cancer → in MeSH, this would be ""Colorectal Neoplasms""
- Liver as the metastatic target → ""Liver Neoplasms, Secondary"" or potentially ""Neoplasm Metastasis""

""The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear.""

- Tumor microenvironment — this is a well-established MeSH term
- The nutritional aspect might also suggest ""Metabolomics"" or metabolic terms, but let me keep going

""Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions.""

- Single-cell analysis — this maps to the MeSH term ""Single-Cell Analysis""
- CD177 — this is a specific antigen, so ""CD177 Antigen"" would be appropriate
- GK+ — glycerol kinase, though I'm not sure if there's a specific MeSH term for that. Glycerol kinase might not have its own heading, but ""Glycerol"" certainly does as a metabolic compound
- Regulatory T cells → ""T-Lymphocytes, Regulatory"" is the standard MeSH heading
- Autologous samples — this might relate to ""Autografts"" or similar, but that seems less central

""Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages.""

- Spatial transcriptomics — this would fall under ""Transcriptome"" or potentially ""Gene Expression Profiling""
- Macrophages — definitely a MeSH term, and given the immunosuppressive context, this is relevant
- Immunosuppression — yes, this is a MeSH term

""Moreover, a selective clonal selection was observed in the metastatic niche, leading to...""

The abstract cuts off here, but I can see it's heading toward describing the clonal selection mechanism.

Now, going back to the histone lactylation aspect — this is critical. H4K5 lactylation is a post-translational modification. In MeSH:
- ""Histones"" is the main term
- For the modification itself, ""Protein Processing, Post-Translational"" would capture lactylation
- ""Lactates"" — since lactylation is driven by lactate, this metabolic term is relevant

The glycerol connection — the title mentions ""glycerol-linked immunosuppressive activity,"" so:
- ""Glycerol"" as a MeSH term for the metabolic link

Let me also think about whether ""Immunosuppression"" should be included — yes, the abstract explicitly mentions ""immunosuppressive macrophages"" and the title references ""immunosuppressive activity.""

Now, should I organize these hierarchically? I think it makes sense to separate primary terms from methodological terms.

Primary terms I'm fairly confident about:
1. Colorectal Neoplasms
2. Neoplasm Metastasis
3. Liver Neoplasms, Secondary
4. T-Lymphocytes, Regulatory
5. Tumor Microenvironment
6. Histones
7. Protein Processing, Post-Translational
8. Lactates
9. Glycerol
10. Macrophages
11. Immunosuppression
12. CD177 Antigen

Methodological terms:
1. Single-Cell Analysis
2. Transcriptome (for spatial transcriptomics)

Should I also suggest subheadings/qualifiers? That would add value. The most relevant would be:
- Colorectal Neoplasms / metabolism (since the study examines metabolic microenvironments)
- T-Lymphocytes, Regulatory / physiology (functional characterization)
- Histones / metabolism (lactylation is a metabolic modification)

I think I should also consider whether ""Clonal Selection"" or similar terms apply — but given the abstract is cut off, I'll focus on what I can clearly identify.

Let me also double-check: is ""Glycerol Kinase"" a MeSH term? I don't believe it has its own heading, so ""Glycerol"" would be the appropriate term for that metabolic pathway.

One more consideration — should I include ""Gene Expression Regulation""? The study involves transcriptomics and feedback loops, but I think the terms I've already identified are more specific and appropriate.

I'm fairly confident in this list. Let me organize it clearly.","Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to","Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to","# Constraints
The question you must answer is from a science domain. You are a senior computational biologist and oncology researcher specializing in tumor immunology and epigenetics. With a PhD and over 15 years of experience analyzing single-cell data and spatial transcriptomics, you possess deep expertise in MeSH indexing and cancer metastasis mechanisms. Your precise, academic sensibility allows you to accurately extract and validate complex biomedical terms from cutting-edge studies. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver.","### Task
Summarize the main finding of the provided biomedical study in exactly one sentence.

### Input Data
**Title:** Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.
**Abstract:** Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to the super-amplification of metastasis-associated clones of GK+ Tregs, suggesting a dominant role of these clones in metastatic immune evasion. Mechanistically, glycerol-derived lactate promotes H4K5 histone lactylation, which upregulates FOXP3 and subsequently GK expression, creating a positive feedback loop that amplifies Treg immunosuppressive activity. Blocking the glycerol metabolic pathway in Tregs combined with anti-PD-1 therapy synergistically curbs tumor progression. Pan-cancer analyses further confirm the potent suppressive activity of CD177+GK+ Tregs across multiple cancer types. Collectively, our findings highlight glycerol metabolism and histone lactylation as critical drivers o

### Constraints
- **Length:** The output must be a single sentence.
- **Focus:** Capture the core mechanistic discovery and its implication.
- **Accuracy:** Base the summary strictly on the provided text, even if the text appears truncated at the end.","This study identifies a glycerol-derived lactate-driven H4K5 histone lactylation feedback loop that upregulates FOXP3 and GK expression in CD177+GK+ regulatory T cells, amplifying their immunosuppressive activity to drive tumor immune evasion in colorectal cancer liver metastases, with therapeutic blockade of this metabolic pathway synergizing with anti-PD-1 therapy to curb tumor progression.","Let me break down what this study is really about. The title mentions H4K5 lactylation, a feedback loop, glycerol, and Treg immunosuppressive activity — so the core is clearly metabolic-epigenetic regulation of Tregs in cancer.

Reading through the abstract, the key discovery chain is: glycerol-derived lactate drives H4K5 histone lactylation, which upregulates FOXP3 and then GK expression, creating a positive feedback loop that amplifies Treg immunosuppressive activity. This was identified in a specific CD177+GK+ Treg subset found in colorectal cancer liver metastases. The therapeutic implication is that blocking the glycerol metabolic pathway synergizes with anti-PD-1 therapy.

So I need to capture: the mechanism (glycerol → lactate → H4K5 lactylation → FOXP3/GK upregulation → feedback loop), the cell type (CD177+GK+ Tregs), the consequence (immunosuppressive activity driving immune evasion), the context (CRC liver metastases), and the therapeutic implication (blocking glycerol metabolism + anti-PD-1 synergy).

That's a lot for one sentence, but the constraint says exactly one sentence. I can use a compound sentence structure with clauses to fit it all in. Let me draft:

""This study identifies a glycerol-derived lactate-driven H4K5 histone lactylation feedback loop that upregulates FOXP3 and GK expression in CD177+GK+ regulatory T cells, amplifying their immunosuppressive activity to drive tumor immune evasion in colorectal cancer liver metastases, with therapeutic blockade of this metabolic pathway synergizing with anti-PD-1 therapy to curb tumor progression.""

That covers the mechanism, the cell type, the consequence, the disease context, and the therapeutic implication — all in one sentence. It's dense but accurate and complete. The pan-cancer confirmation is a secondary point that I can reasonably omit to keep the sentence from becoming unwieldy, since the core discovery and its primary therapeutic implication are fully captured.This study identifies a glycerol-derived lactate-driven H4K5 histone lactylation feedback loop that upregulates FOXP3 and GK expression in CD177+GK+ regulatory T cells, amplifying their immunosuppressive activity to drive tumor immune evasion in colorectal cancer liver metastases, with therapeutic blockade of this metabolic pathway synergizing with anti-PD-1 therapy to curb tumor progression.","Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to the super-amplification of metastasis-associated clones of GK+ Tregs, suggesting a dominant role of these clones in metastatic immune evasion. Mechanistically, glycerol-derived lactate promotes H4K5 histone lactylation, which upregulates FOXP3 and subsequently GK expression, creating a positive feedback loop that amplifies Treg immunosuppressive activity. Blocking the glycerol metabolic pathway in Tregs combined with anti-PD-1 therapy synergistically curbs tumor progression. Pan-cancer analyses further confirm the potent suppressive activity of CD177+GK+ Tregs across multiple cancer types. Collectively, our findings highlight glycerol metabolism and histone lactylation as critical drivers o","Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to the super-amplification of metastasis-associated clones of GK+ Tregs, suggesting a dominant role of these clones in metastatic immune evasion. Mechanistically, glycerol-derived lactate promotes H4K5 histone lactylation, which upregulates FOXP3 and subsequently GK expression, creating a positive feedback loop that amplifies Treg immunosuppressive activity. Blocking the glycerol metabolic pathway in Tregs combined with anti-PD-1 therapy synergistically curbs tumor progression. Pan-cancer analyses further confirm the potent suppressive activity of CD177+GK+ Tregs across multiple cancer types. Collectively, our findings highlight glycerol metabolism and histone lactylation as critical drivers o","# Constraints
The question you must answer is from a science domain. You are a senior cancer immunologist and principal investigator specializing in tumor metabolism and epigenetic regulation. With over 15 years of experience analyzing single-cell data and spatial transcriptomics, you possess deep expertise in how metabolic pathways like glycerol-lactate influence Treg function. Your precise understanding of histone lactylation mechanisms makes you the ideal expert to distill complex biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC).,"### Task
Summarize the main finding of the provided biomedical study in exactly one sentence.

### Input Data
**Title:** Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair.
**Abstract:** Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lactylation (H3K18la), induced by GEM-driven lactate accumulation, as a key epigenetic mechanism of chemoresistance. H3K18la functions as a transcriptional activator of ribosomal protein L11(RPL11) Elevated RPL11 establishes a dual, compartmentalized pro-survival program: in the cytoplasm, RPL11 binds and stabilizes eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) to enhance global protein synthesis; in the nucleus, RPL11 serves as a noncanonical transcriptional coactivator of (ADP-ribose) polymerase 14 (PARP14), augmenting DNA damage repair and attenuating GEM cytotoxicity. Pharmacologic or genetic inhibition of lactate production or RPL11 expression synergizes with GEM to overcome resistance and suppress PDAC progression in xenograft models. These findings define a lactate-H3K18la-RPL11axis that couples metabolic and epigenetic remodeling to translational control and genome maintenance, revealing actionable vulnerabilities in PDAC chemoresistance.

### Constraints
- **Length:** The output must be a single sentence.
- **Focus:** Capture the core mechanism (the axis) and its impact on drug resistance.
- **Tone:** Professional and scientific.",This study identifies a lactate-H3K18la-RPL11 axis that drives gemcitabine resistance in pancreatic ductal adenocarcinoma by epigenetically upregulating RPL11 to concurrently enhance global protein synthesis via EEF1A1 stabilization and DNA damage repair through PARP14 coactivation.,"Okay, I need to summarize this biomedical study in exactly one sentence. Let me break down what's happening here.

The study is about gemcitabine resistance in pancreatic cancer (PDAC). The core finding seems to be this ""lactate-H3K18la-RPL11 axis"" — so gemcitabine causes lactate accumulation, which induces histone H3K18 lactylation, and that in turn activates RPL11 transcription.

So what does RPL11 do? It has a dual role — in the cytoplasm it stabilizes EEF1A1 to boost protein synthesis, and in the nucleus it acts as a transcriptional coactivator of PARP14, which enhances DNA damage repair. Both of these promote survival and resistance to gemcitabine.

The key elements I need to capture: the axis itself (lactate-H3K18la-RPL11), the mechanism (H3K18la upregulates RPL11), the dual downstream effect (protein synthesis via EEF1A1 + DNA repair via PARP14), and the outcome (gemcitabine resistance in PDAC).

Let me think about how to structure this. One sentence, professional scientific tone. I should lead with the main finding — the identification of this axis — then explain the mechanism and its consequences.

Something like: ""This study identifies a lactate-H3K18la-RPL11 axis that drives gemcitabine resistance in pancreatic ductal adenocarcinoma by epigenetically upregulating RPL11 to concurrently enhance global protein synthesis via EEF1A1 stabilization and DNA damage repair through PARP14 coactivation.""

Let me check — does this capture everything? The axis is named, the epigenetic mechanism is noted (H3K18la upregulating RPL11), both downstream arms are included (EEF1A1 for protein synthesis, PARP14 for DNA repair), and the outcome is clear (gemcitabine resistance in PDAC). It's one sentence. The tone is professional and scientific.

I could mention the therapeutic angle — that inhibiting lactate or RPL11 overcomes resistance — but that might make the sentence too long and dilute the focus on the core mechanism. The constraints say to focus on the axis and its impact on drug resistance, so I think the mechanism-centered version is better.

I think this works well. It's comprehensive without being unwieldy, and it hits all the required elements.","Title: Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair. | Abstract: Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lactylation (H3K18la), induced by GEM-driven lactate accumulation, as a key epigenetic mechanism of chemoresistance. H3K18la functions as a transcriptional activator of ribosomal protein L11(RPL11) Elevated RPL11 establishes a dual, compartmentalized pro-survival program: in the cytoplasm, RPL11 binds and stabilizes eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) to enhance global protein synthesis; in the nucleus, RPL11 serves as a noncanonical transcriptional coactivator of (ADP-ribose) polymerase 14 (PARP14), augmenting DNA damage repair and attenuating GEM cytotoxicity. Pharmacologic or genetic inhibition of lactate production or RPL11 expression synergizes with GEM to overcome resistance and suppress PDAC progression in xenograft models. These findings define a lactate-H3K18la-RPL11axis that couples metabolic and epigenetic remodeling to translational control and genome maintenance, revealing actionable vulnerabilities in PDAC chemoresistance.","Title: Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair. | Abstract: Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lactylation (H3K18la), induced by GEM-driven lactate accumulation, as a key epigenetic mechanism of chemoresistance. H3K18la functions as a transcriptional activator of ribosomal protein L11(RPL11) Elevated RPL11 establishes a dual, compartmentalized pro-survival program: in the cytoplasm, RPL11 binds and stabilizes eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) to enhance global protein synthesis; in the nucleus, RPL11 serves as a noncanonical transcriptional coactivator of (ADP-ribose) polymerase 14 (PARP14), augmenting DNA damage repair and attenuating GEM cytotoxicity. Pharmacologic or genetic inhibition of lactate production or RPL11 expression synergizes with GEM to overcome resistance and suppress PDAC progression in xenograft models. These findings define a lactate-H3K18la-RPL11axis that couples metabolic and epigenetic remodeling to translational control and genome maintenance, revealing actionable vulnerabilities in PDAC chemoresistance.","# Constraints
The question you must answer is from a science domain. You are a senior oncology researcher and molecular biologist specializing in pancreatic cancer epigenetics. With a PhD and 15 years of lab experience, you expertly interpret complex metabolic pathways and histone modifications. Your precise analysis bridges basic science and clinical application for chemoresistance. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | Signal Transduction | Receptors, Chimeric Antigen | Cell Proliferation | CD8-Positive T-Lymphocytes | Immunotherapy, Adoptive | CD28 Antigens | Mitochondria | Polylactic Acid-Polyglycolic Acid Copolymer | Lymphocyte Activation | ErbB Receptors","Identify and list the Medical Subject Headings (MeSH) terms that appropriately index the following scientific study.

<study_content>
Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness 
</study_content>","Based on the provided study, the following Medical Subject Headings (MeSH) terms appropriately index the scientific content:

* Humans
* Receptors, Chimeric Antigen
* T-Lymphocytes
* CD8-Positive T-Lymphocytes
* Lymphocyte Activation
* Immunotherapy, Adoptive
* Cell Proliferation
* Cell Survival
* Ex Vivo Techniques
* Signal Transduction
* CD28 Antigens
* ErbB Receptors
* Polylactic Acid-Polyglycolic Acid Copolymer
* Microspheres
* Drug Delivery Systems
* DNA Nanostructures
* Antibodies, Monoclonal
* Mitochondria","Let me analyze this study systematically to identify the appropriate MeSH terms.

The study is about engineering programmable particles (CAREp) to enhance CAR-T cell expansion ex vivo. Let me break down the key components:

**Subject/Population:**
- Human CAR-T cells (CD8+ specifically) → ""Humans"", ""T-Lymphocytes"", ""CD8-Positive T-Lymphocytes""
- CAR constructs mentioned → ""Receptors, Chimeric Antigen""

**Biological Process:**
- The study focuses on T-cell expansion and proliferation → ""Cell Proliferation""
- Persistence and survival of cells → ""Cell Survival""
- External stimulation/activation of T-cells → ""Lymphocyte Activation""
- Signaling rewiring mentioned in title → ""Signal Transduction""
- This is adoptive immunotherapy context → ""Immunotherapy, Adoptive""

**Methodology/Technique:**
- Ex vivo expansion → ""Ex Vivo Techniques""

**Molecular Components:**
- CD28 costimulatory antibodies → ""CD28 Antigens""
- a-EGFR (epidermal growth factor receptor) CAR → I need to map this. EGFR is part of the ErbB receptor family → ""ErbB Receptors""
- 4-1BBζ and CD28ζ constructs are costimulatory domains, but these are subsumed under the chimeric antigen receptor heading

**Material/Particle Engineering:**
- PLGA microparticles → ""Polylactic Acid-Polyglycolic Acid Copolymer"", ""Microspheres""
- DNA-scaffolded structure → ""DNA Nanostructures""
- Drug delivery context → ""Drug Delivery Systems""
- Monoclonal antibodies displayed → ""Antibodies, Monoclonal""

**Additional Biological Elements:**
- Mitochondrial fitness mentioned → ""Mitochondria""

Let me reconsider a few items. The 4-1BB and CD28 costimulatory molecules... CD28 has its own MeSH term. 4-1BB (TNFRSF9) doesn't have a specific MeSH heading that's commonly used, so I'll focus on CD28 Antigens which is explicitly mentioned.

The anti-EGFR specificity—EGFR is indeed under ""Receptors, erbB-1"" in the MeSH hierarchy, so ""ErbB Receptors"" captures this.

Let me verify I'm not missing anything major. The study touches on effector function but that's inherent to T-Lymphocyte Activation. The tumor-cell comparison doesn't make this an oncology study per se—the focus is the methodology.

I should organize these logically, perhaps by category for clarity.

Here's my compiled list:

Based on the provided study, the following Medical Subject Headings (MeSH) terms appropriately index the scientific content:

* Humans
* Receptors, Chimeric Antigen
* T-Lymphocytes
* CD8-Positive T-Lymphocytes
* Lymphocyte Activation
* Immunotherapy, Adoptive
* Cell Proliferation
* Cell Survival
* Ex Vivo Techniques
* Signal Transduction
* CD28 Antigens
* ErbB Receptors
* Polylactic Acid-Polyglycolic Acid Copolymer
* Microspheres
* Drug Delivery Systems
* DNA Nanostructures
* Antibodies, Monoclonal
* Mitochondria","Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness ","Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness ","# Constraints
The question you must answer is from a science domain. You are a senior biomedical librarian and immunology researcher specializing in CAR-T cell therapies. With a PhD in Molecular Biology and 15 years of experience indexing oncology studies, you possess encyclopedic knowledge of MeSH terminologies and T-cell signaling pathways. Your precise expertise ensures accurate mapping of complex genetic engineering concepts to standard medical subject headings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments.","# Task: Biomedical Study Summary

Generate a single-sentence summary of the main finding from the study provided below.

## Constraints
- **Length**: Exactly one sentence.
- **Focus**: Capture the primary conclusion regarding therapeutic outcomes.
- **Tone**: Professional and scientific.

## Input Data
**Title**: Perioperative immunotherapy in head and neck squamous cell carcinoma.
**Abstract**: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event-free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperative immunotherapy strategies. Although the former approach fits into a conventional adjuvant framework, biological insights suggest that neoadjuvant delivery enables effective immune priming extending therapeutic approaches. Together, these advances redefine therapeutic strategies in resectable HNSCC and highlight the potential of perioperative immunotherapy to improve long-term outcomes.",Recent phase III trials establish that adjuvant nivolumab and perioperative pembrolizumab significantly improve survival outcomes in resectable head and neck squamous cell carcinoma—disease-free survival with adjuvant nivolumab and event-free survival with perioperative pembrolizumab—supporting a paradigm shift toward integrated perioperative immunotherapy strategies.,"Alright, I need to write a single-sentence summary of the main finding from this study about perioperative immunotherapy in head and neck squamous cell carcinoma (HNSCC). Let me break down what's in this abstract.

The abstract is talking about several key points:
1. Current outcomes for resectable HNSCC are suboptimal - high recurrence, treatment toxicity
2. Immune checkpoint inhibitors have been moved into perioperative/adjuvant settings
3. Two specific phase III trial results:
   - Adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs
   - Perioperative pembrolizumab prolonged event-free survival in resectable locally advanced HNSCCs
4. These support a shift toward integrated perioperative immunotherapy strategies
5. There's mention of neoadjuvant delivery enabling immune priming
6. The conclusion is that these advances redefine therapeutic strategies and highlight potential to improve long-term outcomes

The main finding here is really about the two phase III trials showing survival benefits with these immunotherapy approaches. The primary conclusion regarding therapeutic outcomes is that both adjuvant nivolumab and perioperative pembrolizumab improve survival outcomes (DFS and EFS respectively) in resectable HNSCC, supporting a paradigm shift toward perioperative immunotherapy.

Let me draft a sentence:

""Recent phase III trials demonstrate that adjuvant nivolumab and perioperative pembrolizumab significantly improve survival outcomes in resectable head and neck squamous cell carcinoma—disease-free survival with adjuvant nivolumab in pathologic high-risk cases and event-free survival with perioperative pembrolizumab in locally advanced disease—supporting a paradigm shift toward integrated perioperative immunotherapy strategies.""

Let me check this:
- One sentence? Yes.
- Captures primary conclusion regarding therapeutic outcomes? Yes - mentions both drugs, their survival benefits, and the paradigm shift.
- Professional and scientific tone? Yes.

The sentence is a bit long but it's comprehensive. I'm specifying which drug improved which outcome and in which patient population, which is important for precision. The em-dashes help organize the information within the single sentence structure.

Actually, let me reconsider whether I need to specify the patient populations (pathologic high-risk, locally advanced). The prompt asks for the main finding regarding therapeutic outcomes. Including the populations adds precision but also length. I think it's valuable to include because it specifies who benefits, which is clinically important.

Let me refine slightly:

""Recent phase III trials establish that adjuvant nivolumab and perioperative pembrolizumab significantly improve survival outcomes in resectable head and neck squamous cell carcinoma—disease-free survival with adjuvant nivolumab in pathologic high-risk resected cases and event-free survival with perioperative pembrolizumab in locally advanced disease—supporting a paradigm shift toward integrated perioperative immunotherapy strategies.""

Hmm, ""resected cases"" is a bit awkward. Let me adjust:

""Recent phase III trials establish that adjuvant nivolumab and perioperative pembrolizumab significantly improve survival outcomes in resectable head and neck squamous cell carcinoma—disease-free survival with adjuvant nivolumab and event-free survival with perioperative pembrolizumab—supporting a paradigm shift toward integrated perioperative immunotherapy strategies.""

Actually, I think I can simplify by removing the specific population descriptors and just focus on the drugs and their outcomes. The abstract's main message is that these two trials collectively support the shift toward perioperative immunotherapy. Let me try a cleaner version:

""Recent phase III trials establish that adjuvant nivolumab and perioperative pembrolizumab significantly improve survival outcomes in resectable head and neck squamous cell carcinoma—disease-free survival with adjuvant nivolumab and event-free survival with perioperative pembrolizumab—supporting a paradigm shift toward integrated perioperative immunotherapy strategies.""

This is cleaner. It captures:
- The trial type (phase III)
- Both interventions (adjuvant nivolumab, perioperative pembrolizumab)
- The outcomes (DFS, EFS)
- The disease (resectable HNSCC)
- The conclusion (paradigm shift toward perioperative immunotherapy)

I think this works well. It's one sentence, captures the main finding about therapeutic outcomes, and maintains a professional scientific tone. The em-dashes allow me to specify which drug corresponds to which outcome without creating a run-on sentence or needing multiple sentences.

Let me do one final check on the language - ""establish"" is appropriate for phase III trial results. ""Significantly improve"" accurately reflects the abstract's language about improved DFS and prolonged EFS. ""Paradigm shift"" captures the abstract's language about redefining therapeutic strategies.

I'm satisfied with this version. It's precise, comprehensive, and meets all the constraints.","Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event-free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperative immunotherapy strategies. Although the former approach fits into a conventional adjuvant framework, biological insights suggest that neoadjuvant delivery enables effective immune priming extending therapeutic approaches. Together, these advances redefine therapeutic strategies in resectable HNSCC and highlight the potential of perioperative immunotherapy to improve long-term outcomes.","Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event-free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperative immunotherapy strategies. Although the former approach fits into a conventional adjuvant framework, biological insights suggest that neoadjuvant delivery enables effective immune priming extending therapeutic approaches. Together, these advances redefine therapeutic strategies in resectable HNSCC and highlight the potential of perioperative immunotherapy to improve long-term outcomes.","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and clinical researcher specializing in head and neck cancers, currently leading perioperative immunotherapy trials at a major academic medical center. With over 15 years of experience, you possess deep expertise in interpreting phase III trial data for HNSCC and translating complex biological insights into clear clinical summaries for peers. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge.,"# Task: Summarize Biomedical Study Finding

## Instructions
Analyze the provided biomedical study text below and generate a **single-sentence summary** of its main finding.

### Constraints
- **Length**: Exactly one sentence.
- **Focus**: Highlight the primary efficacy or safety outcome.
- **Tone**: Professional and scientific.
- **Accuracy**: Base the summary strictly on the provided text.

## Input Text
Title: Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma. | Abstract: Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evaluated the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC. This open-label, multicenter, phase IIa study enrolled patients with locally advanced HCC refractory to standard care. Patients achieving stable disease (SD) or better after two HAIC cycles (5-fluorouracil and cisplatin) underwent two additional HAIC cycles followed by hepatic arterial NK cell infusion for up to two cycles. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR). Secondary endpoints included investigator-assessed ORR, disease control rate (DCR), duration of response (DOR), time to progression (TTP), overall survival (OS), safety, and immunologic response. Tumor response was assessed per modified RECIST for HCC. Of 17 enrolled patients, 16 were evaluable. IRC-assessed ORR was 68.75% (exact 95% confidence interval, 41.34-88.98) [complete response (CR): 18.75%; partial response (PR): 50.00%], and investigator-assessed ORR was 62.50%. Both assessments yielded a DCR of 100%. Median DOR was 12.65 and 10.48 months by IRC and investigator assessment, respectively. Median investigator-assessed TTP was 16.82 months; ","In a phase IIa trial of patients with locally advanced hepatocellular carcinoma refractory to standard care, combining locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy achieved an independent review committee-assessed objective response rate of 68.75% and a disease control rate of 100%.","Let me analyze this biomedical study text carefully. The title tells me this is a Phase IIa trial combining autologous NK cell therapy with HAIC for locally advanced HCC. The abstract describes the study design — patients refractory to standard care, the treatment protocol involving HAIC cycles followed by hepatic arterial NK cell infusion.

Now I need to identify the primary finding. The primary endpoint was IRC-assessed ORR, which was 68.75%. The DCR was 100%. Those are the key efficacy numbers. The text appears to be cut off, but I have enough to work with for the main efficacy outcome.

I need to construct exactly one sentence that captures the main finding. Let me think about what's essential: the patient population (locally advanced HCC refractory to standard care), the intervention (NK cell therapy combined with HAIC), and the primary efficacy results (ORR 68.75%, DCR 100%).

Let me draft this: ""In a phase IIa trial of patients with locally advanced hepatocellular carcinoma refractory to standard care, combining locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy achieved an independent review committee-assessed objective response rate of 68.75% and a disease control rate of 100%.""

That's one sentence, professional tone, highlights the primary efficacy outcome, and is strictly based on the provided text. I included the DCR because it was a notable secondary endpoint at 100%, which is clinically meaningful. I should make sure I'm not adding anything not in the text — all these figures come directly from the abstract. The sentence flows well and captures the essential finding without unnecessary detail about secondary endpoints like DOR or TTP, which would make it too long and unfocused.

I think this works. It's accurate, concise, and meets all the constraints.","Title: Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma. | Abstract: Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evaluated the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC. This open-label, multicenter, phase IIa study enrolled patients with locally advanced HCC refractory to standard care. Patients achieving stable disease (SD) or better after two HAIC cycles (5-fluorouracil and cisplatin) underwent two additional HAIC cycles followed by hepatic arterial NK cell infusion for up to two cycles. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR). Secondary endpoints included investigator-assessed ORR, disease control rate (DCR), duration of response (DOR), time to progression (TTP), overall survival (OS), safety, and immunologic response. Tumor response was assessed per modified RECIST for HCC. Of 17 enrolled patients, 16 were evaluable. IRC-assessed ORR was 68.75% (exact 95% confidence interval, 41.34-88.98) [complete response (CR): 18.75%; partial response (PR): 50.00%], and investigator-assessed ORR was 62.50%. Both assessments yielded a DCR of 100%. Median DOR was 12.65 and 10.48 months by IRC and investigator assessment, respectively. Median investigator-assessed TTP was 16.82 months; ","Title: Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma. | Abstract: Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evaluated the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC. This open-label, multicenter, phase IIa study enrolled patients with locally advanced HCC refractory to standard care. Patients achieving stable disease (SD) or better after two HAIC cycles (5-fluorouracil and cisplatin) underwent two additional HAIC cycles followed by hepatic arterial NK cell infusion for up to two cycles. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR). Secondary endpoints included investigator-assessed ORR, disease control rate (DCR), duration of response (DOR), time to progression (TTP), overall survival (OS), safety, and immunologic response. Tumor response was assessed per modified RECIST for HCC. Of 17 enrolled patients, 16 were evaluable. IRC-assessed ORR was 68.75% (exact 95% confidence interval, 41.34-88.98) [complete response (CR): 18.75%; partial response (PR): 50.00%], and investigator-assessed ORR was 62.50%. Both assessments yielded a DCR of 100%. Median DOR was 12.65 and 10.48 months by IRC and investigator assessment, respectively. Median investigator-assessed TTP was 16.82 months; ","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and clinical researcher specializing in hepatocellular carcinoma and immunotherapy. With over 15 years of experience interpreting phase II trials, you possess deep expertise in NK cell therapies and hepatic arterial infusion. Your precise, evidence-based approach ensures accurate summarization of complex biomedical data for medical professionals. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer.","### Task
Summarize the main finding of the provided biomedical study abstract into a single, concise sentence.

### Input Data
**Title:** Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.
**Abstract:** CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespecified one-sided 90% confidence interval was 56.5%, exceeding the 46% historical benchmark, and the primary endpoint was met. Twelve- and 24-month overall survival were 93% and 73%, respectively, and the confirmed objective response rate was 81%. Canakinumab-related grade 3-4 events included neutropenia (n = 5), febrile neutropenia (n = 1), lymphopenia (n = 1), lung infection (n = 1), fatigue (n = 1), and hypertension (n = 1); no canakinumab-related deaths occurred. Pneumonitis of any attribution occurred in 9 of 37 patients (24%; grade 2, n = 7; grade 3, n = 2). Peripheral immune cell profiling showed attenuated expansion of myeloid-derived suppressor cells and CTLA-4-expressing CD8 + T-cel

### Constraints
- **Length:** Exactly one sentence.
- **Focus:** Highlight the primary outcome (whether the main goal of the study was achieved).
- **Accuracy:** Base the summary strictly on the provided text.","The phase I/II CHORUS trial met its primary endpoint, demonstrating that canakinumab combined with concurrent chemoradiation and durvalumab consolidation achieved a 24-month progression-free survival rate of 67% in unresectable stage III non-small cell lung cancer, exceeding the 46% historical benchmark.","Let me break down this abstract. The key elements I need to capture:

1. **Study design**: Phase I/II CHORUS trial, single-arm
2. **Intervention**: Canakinumab (anti-IL-1β) + chemoradiation + durvalumab consolidation
3. **Population**: Unresectable stage III NSCLC
4. **Primary endpoint**: 24-month PFS from radiotherapy initiation
5. **Key result**: 24-month PFS was 67%, lower bound of 90% CI was 56.5%, which exceeded the 46% historical benchmark → primary endpoint MET
6. **Secondary endpoints**: OS (93% at 12mo, 73% at 24mo), ORR 81%, safety data

The constraint asks me to focus on the primary outcome — whether the main goal was achieved. So I need to center the summary on the fact that the primary endpoint was met, with the key supporting data.

Let me think about what's essential vs. what can be cut. The safety data is secondary to the primary outcome focus. The immune cell profiling data is interesting mechanistically but not the main finding. The OS and ORR are secondary endpoints. I should mention the intervention and population briefly for context, then focus on the primary outcome result.

Drafting: ""The phase I/II CHORUS trial met its primary endpoint, demonstrating that canakinumab combined with concurrent chemoradiation and durvalumab consolidation achieved a 24-month progression-free survival rate of 67% in unresectable stage III non-small cell lung cancer, exceeding the 46% historical benchmark.""

Let me check this against the constraints:
- One sentence? Yes.
- Highlights primary outcome? Yes — leads with ""met its primary endpoint"" and includes the specific PFS data and benchmark comparison.
- Accurate to the text? Yes — 67% PFS, 46% benchmark, the combination therapy described correctly, population correct.
- No extraneous information? I've omitted safety, ORR, OS, and mechanistic data, which is appropriate given the focus constraint.

This captures the essential finding concisely. The sentence flows logically: states the trial met its endpoint, describes the intervention, gives the key result, and notes it exceeded the benchmark. That's the core message a clinician would want to know from this abstract.","Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespecified one-sided 90% confidence interval was 56.5%, exceeding the 46% historical benchmark, and the primary endpoint was met. Twelve- and 24-month overall survival were 93% and 73%, respectively, and the confirmed objective response rate was 81%. Canakinumab-related grade 3-4 events included neutropenia (n = 5), febrile neutropenia (n = 1), lymphopenia (n = 1), lung infection (n = 1), fatigue (n = 1), and hypertension (n = 1); no canakinumab-related deaths occurred. Pneumonitis of any attribution occurred in 9 of 37 patients (24%; grade 2, n = 7; grade 3, n = 2). Peripheral immune cell profiling showed attenuated expansion of myeloid-derived suppressor cells and CTLA-4-expressing CD8 + T-cel","Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespecified one-sided 90% confidence interval was 56.5%, exceeding the 46% historical benchmark, and the primary endpoint was met. Twelve- and 24-month overall survival were 93% and 73%, respectively, and the confirmed objective response rate was 81%. Canakinumab-related grade 3-4 events included neutropenia (n = 5), febrile neutropenia (n = 1), lymphopenia (n = 1), lung infection (n = 1), fatigue (n = 1), and hypertension (n = 1); no canakinumab-related deaths occurred. Pneumonitis of any attribution occurred in 9 of 37 patients (24%; grade 2, n = 7; grade 3, n = 2). Peripheral immune cell profiling showed attenuated expansion of myeloid-derived suppressor cells and CTLA-4-expressing CD8 + T-cel","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and clinical trial investigator specializing in thoracic malignancies. With 20 years of experience in immunotherapy and chemoradiation, you possess deep expertise in interpreting phase I/II trial data. Your analytical precision allows you to distill complex statistical outcomes into clear clinical insights for the medical community. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,Cellular immunotherapies have shown great promise in the treatment of various diseases.,"# Task: Summarize Biomedical Study Finding

**Objective**: Analyze the provided biomedical study text and summarize its main finding in exactly one sentence.

**Instructions**:
1. Read the study title and abstract provided below.
2. Identify the primary outcome regarding safety, tissue distribution, or antiviral activity.
3. Construct a single, grammatically complete sentence that captures this main finding.
4. Ensure the summary is concise and accurate based *only* on the provided text.

**Input Data**:
Title: Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. | Abstract: Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic ""eat me"" signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4+ T cells infected with simian immunodeficiency virus (SIV) in vitro. In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and s","In SIV-infected rhesus macaques, the autologous infusion of CER-1236 T cells was well tolerated, with neither animal exhibiting clinical illness or physiological changes beyond those typically associated with SIV infection.","The prompt asks me to summarize a biomedical study's main finding in exactly one sentence. Let me carefully read through the title and abstract.

The title tells me this is about safety of autologous CER T cell infusion in nonhuman primates. The abstract gives me the background: CER-engineered T cells use TIM-4 domains to target phosphatidylserine (PS) — a pro-phagocytic signal — and enhance phagocytosis and T-cell cytotoxicity. HIV/SIV infection induces PS exposure, and these cells have been shown to kill SIV-infected CD4+ T cells in vitro.

Now the actual study: two rhesus macaques were infused with CER-1236 T cells after SIV infection, ART, and ART cessation. They evaluated safety, tissue distribution, and antiviral activity.

The key results stated: infusions were well tolerated. Neither macaque showed clinical illness or changes in vital signs, serum chemistry, hematology, or other parameters beyond typical SIV infection observations. Post-infusion proliferation was limited (text cuts off there).

The primary outcome emphasized here is clearly safety — that's the title's focus and the most detailed result reported. The tissue distribution and antiviral activity results appear to be cut off or minimal in this excerpt. So my sentence should center on the safety finding.

Let me draft: ""In SIV-infected rhesus macaques, the autologous infusion of CER-1236 T cells was well tolerated, with neither animal exhibiting clinical illness or physiological changes beyond those typically associated with SIV infection.""

That's one grammatically complete sentence. It's accurate to the text — doesn't add anything not stated. It captures the main finding concisely. Good.In SIV-infected rhesus macaques, the autologous infusion of CER-1236 T cells was well tolerated, with neither animal exhibiting clinical illness or physiological changes beyond those typically associated with SIV infection.","Title: Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. | Abstract: Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic ""eat me"" signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4+ T cells infected with simian immunodeficiency virus (SIV) in vitro. In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and s","Title: Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. | Abstract: Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic ""eat me"" signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4+ T cells infected with simian immunodeficiency virus (SIV) in vitro. In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and s","# Constraints
The question you must answer is from a science domain. You are a senior translational immunologist and virologist specializing in cellular therapies for infectious diseases. With over 15 years of experience designing preclinical nonhuman primate studies, you expertly interpret complex abstracts on CAR/CER T-cell safety and efficacy. Your background bridges rigorous academic research and clinical trial development, making you ideal for summarizing high-level biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options.,"# Task: Biomedical Study Summary

Generate a concise, one-sentence summary of the main finding from the provided biomedical study text below.

## Constraints
- **Length**: Exactly one sentence.
- **Focus**: Capture the primary therapeutic mechanism and outcome.
- **Accuracy**: Base the summary strictly on the provided text.

## Input Text
Title: Zingiberen Newsaponin Enhances Antitumor Immunity in Anaplastic Thyroid Carcinoma Via Induction of Autophagy-Dependent Pyroptosis. | Abstract: Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options. Although immunotherapy has revolutionized the oncological landscape, the efficacy of Programmed Cell Death Protein 1 (PD-1) blockade as a monotherapy remains underwhelming in ATC. Consequently, identifying novel agents capable of triggering immunogenic cell death (ICD) to sensitize ATC to immune checkpoint inhibitors is a critical clinical priority. Through high-throughput screening of 3200 compounds, Zingiberen newsaponin (ZN) was identified as a lead anti-ATC agent. Its therapeutic efficacy was evaluated using ATC cell lines, patient-derived organoids, and xenograft models. Mechanistic investigations were conducted via pharmacological inhibition, genetic knockout, and Western blotting to examine the autophagy-pyroptosis axis. Furthermore, an immunocompetent murine ATC model was employed to assess the synergistic effects of ZN and anti-PD-1 therapy on the tumor immune microenvironment through immunohistochemical analysis of T-cell infiltration. ZN exhibited potent antiproliferative activity against ATC cells with half-maximal inhibitory concentration values ranging from 1.95 to 2.98 μM. Morphological assessment and biochemical assays (Lactate dehydrogenase, interleukin-1 beta, and high mobility group box 1 release) confirmed that ZN induces Gasdermin E (GSDME)-med","Zingiberen newsaponin suppresses anaplastic thyroid carcinoma and enhances antitumor immunity by inducing autophagy-dependent, GSDME-mediated pyroptosis, thereby sensitizing the malignancy to anti-PD-1 therapy.","Okay, let me parse this prompt. I need to generate a one-sentence summary of a biomedical study about Zingiberen newsaponin (ZN) in anaplastic thyroid carcinoma (ATC). The summary must capture the primary therapeutic mechanism and outcome, based strictly on the provided text.

Let me break down the key information from the abstract:

1. **Context**: ATC is lethal, dismal prognosis, limited therapeutic options. PD-1 blockade monotherapy is underwhelming in ATC. Need novel agents triggering immunogenic cell death (ICD) to sensitize ATC to immune checkpoint inhibitors.

2. **Agent identified**: Zingiberen newsaponin (ZN) — found through high-throughput screening of 3200 compounds as a lead anti-ATC agent.

3. **Efficacy evaluated**: ATC cell lines, patient-derived organoids, xenograft models. ZN showed potent antiproliferative activity (IC50 1.95–2.98 μM).

4. **Mechanism investigated**: autophagy-pyroptosis axis. Pharmacological inhibition, genetic knockout, Western blotting. Morphological and biochemical assays (LDH, IL-1β, HMGB1 release) confirmed ZN induces GSDME-mediated... (text cuts off here, but clearly ""pyroptosis"" given the title and context).

5. **Immune model**: Immunocompetent murine ATC model assessed synergistic effects of ZN + anti-PD-1 therapy on tumor immune microenvironment via T-cell infiltration analysis.

6. **Title confirms**: ""Zingiberen Newsaponin Enhances Antitumor Immunity in Anaplastic Thyroid Carcinoma Via Induction of Autophagy-Dependent Pyroptosis.""

So the primary finding: ZN suppresses ATC (antiproliferative activity) and enhances antitumor immunity by inducing autophagy-dependent pyroptosis (specifically GSDME-mediated), which sensitizes ATC to anti-PD-1 therapy (synergistic effect with immune checkpoint inhibition).

Now I need to distill this into exactly one sentence capturing the therapeutic mechanism and outcome.

Key elements to include:
- Agent: Zingiberen newsaponin (ZN)
- Disease: anaplastic thyroid carcinoma (ATC)
- Mechanism: autophagy-dependent, GSDME-mediated pyroptosis
- Outcome: suppresses ATC / enhances antitumor immunity / sensitizes to anti-PD-1 therapy

Let me draft: ""Zingiberen newsaponin suppresses anaplastic thyroid carcinoma and enhances antitumor immunity by inducing autophagy-dependent, GSDME-mediated pyroptosis, thereby sensitizing the malignancy to anti-PD-1 therapy.""

That captures the agent, disease, mechanism (autophagy-dependent pyroptosis via GSDME), and outcome (tumor suppression + immune enhancement + sensitization to anti-PD-1). It's one sentence. Let me verify accuracy against the text — yes, all these elements are explicitly stated or strongly implied.

Could I make it more concise? Let me see... ""Zingiberen newsaponin induces autophagy-dependent, GSDME-mediated pyroptosis in anaplastic thyroid carcinoma, suppressing tumor growth and sensitizing the malignancy to anti-PD-1 immunotherapy."" This is also good, but I think including ""enhances antitumor immunity"" more directly reflects the title's framing.

I'll go with my first draft — it's comprehensive, accurate, and flows well as a single sentence.","Title: Zingiberen Newsaponin Enhances Antitumor Immunity in Anaplastic Thyroid Carcinoma Via Induction of Autophagy-Dependent Pyroptosis. | Abstract: Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options. Although immunotherapy has revolutionized the oncological landscape, the efficacy of Programmed Cell Death Protein 1 (PD-1) blockade as a monotherapy remains underwhelming in ATC. Consequently, identifying novel agents capable of triggering immunogenic cell death (ICD) to sensitize ATC to immune checkpoint inhibitors is a critical clinical priority. Through high-throughput screening of 3200 compounds, Zingiberen newsaponin (ZN) was identified as a lead anti-ATC agent. Its therapeutic efficacy was evaluated using ATC cell lines, patient-derived organoids, and xenograft models. Mechanistic investigations were conducted via pharmacological inhibition, genetic knockout, and Western blotting to examine the autophagy-pyroptosis axis. Furthermore, an immunocompetent murine ATC model was employed to assess the synergistic effects of ZN and anti-PD-1 therapy on the tumor immune microenvironment through immunohistochemical analysis of T-cell infiltration. ZN exhibited potent antiproliferative activity against ATC cells with half-maximal inhibitory concentration values ranging from 1.95 to 2.98 μM. Morphological assessment and biochemical assays (Lactate dehydrogenase, interleukin-1 beta, and high mobility group box 1 release) confirmed that ZN induces Gasdermin E (GSDME)-med","Title: Zingiberen Newsaponin Enhances Antitumor Immunity in Anaplastic Thyroid Carcinoma Via Induction of Autophagy-Dependent Pyroptosis. | Abstract: Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options. Although immunotherapy has revolutionized the oncological landscape, the efficacy of Programmed Cell Death Protein 1 (PD-1) blockade as a monotherapy remains underwhelming in ATC. Consequently, identifying novel agents capable of triggering immunogenic cell death (ICD) to sensitize ATC to immune checkpoint inhibitors is a critical clinical priority. Through high-throughput screening of 3200 compounds, Zingiberen newsaponin (ZN) was identified as a lead anti-ATC agent. Its therapeutic efficacy was evaluated using ATC cell lines, patient-derived organoids, and xenograft models. Mechanistic investigations were conducted via pharmacological inhibition, genetic knockout, and Western blotting to examine the autophagy-pyroptosis axis. Furthermore, an immunocompetent murine ATC model was employed to assess the synergistic effects of ZN and anti-PD-1 therapy on the tumor immune microenvironment through immunohistochemical analysis of T-cell infiltration. ZN exhibited potent antiproliferative activity against ATC cells with half-maximal inhibitory concentration values ranging from 1.95 to 2.98 μM. Morphological assessment and biochemical assays (Lactate dehydrogenase, interleukin-1 beta, and high mobility group box 1 release) confirmed that ZN induces Gasdermin E (GSDME)-med","# Constraints
The question you must answer is from a science domain. You are a senior oncology researcher and molecular biologist specializing in thyroid carcinoma and immunotherapy. With a PhD and 15 years of experience in translational medicine, you expertly interpret complex mechanisms like autophagy-dependent pyroptosis. Your work bridges high-throughput screening and clinical application, making you the ideal authority to summarize this study's findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | CD28 Antigens | Receptors, Chimeric Antigen | Animals | Immunotherapy, Adoptive | Mice | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Adolescent | Child | Female | Mice, Inbred NOD | Male | CRISPR-Cas Systems","Analyze the provided biomedical study excerpt and list the Medical Subject Headings (MeSH) terms that best index this research.

**Study Excerpt:**
Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD2","Based on the provided study excerpt, the following Medical Subject Headings (MeSH) terms best index this research:

**Disease Targets**
* **Precursor T-Cell Lymphoblastic Leukemia-Lymphoma** (Covers T-ALL)
* **Lymphoma, T-Cell** (Covers nodal T-follicular helper cell lymphomas)

**Therapeutic Agents & Targets**
* **Receptors, Chimeric Antigen** (The CAR component)
* **Immunotherapy, Adoptive** (The therapeutic modality)
* **T-Lymphocytes** (The effector cells)
* **CD28 Antigens** (The specific target antigen and gene knocked out)
* **Antigens, CD7** (The alternative target mentioned)

**Methodology & Technology**
* **CRISPR-Cas Systems** (The tool used for CD28 knockout)
* **Gene Knockout Techniques** (The process used to prevent fratricide)
* **Cell Line, Tumor**","Let me break down this study excerpt. The title mentions targeting CD28 on T lineage malignancies using CAR T cells. The abstract discusses T-ALL, nodal T-follicular helper cell lymphomas, CD28 as a target, CRISPR/Cas9 knockout, and anti-CD28 CAR T cells.

Let me work through the MeSH terms systematically.

**Disease entities:**
T-ALL — in MeSH, this is ""Precursor T-Cell Lymphoblastic Leukemia-Lymphoma."" That's the standard heading for T-ALL.

Nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F) — these are T-cell lymphomas. The MeSH tree would have these under ""Lymphoma, T-Cell."" I could also consider ""Lymphoma, T-Cell, Peripheral"" but the broader ""Lymphoma, T-Cell"" is safer since nTFHL subtypes are relatively new classifications.

**Therapeutic approach:**
CAR T cells — the MeSH term is ""Receptors, Chimeric Antigen."" This was introduced relatively recently and is the standard heading for CAR constructs.

Adoptive immunotherapy — ""Immunotherapy, Adoptive"" is the correct MeSH term for transferring engineered immune cells.

T-lymphocytes — ""T-Lymphocytes"" covers the effector cells being used.

**Molecular targets:**
CD28 — ""Antigens, CD28"" or ""CD28 Antigens""? Let me think... The standard MeSH heading is ""Antigens, CD28"" — wait, actually MeSH uses ""Antigens, CD28"" as the heading. No, let me reconsider. MeSH headings for CD antigens follow the pattern ""Antigens, CD[number]."" So it would be ""Antigens, CD28."" Hmm, but I've also seen ""CD28 Antigens"" used. Let me go with ""Antigens, CD28"" as that follows the standard MeSH naming convention... Actually, I need to be careful here. The MeSH heading is ""Antigens, CD28.""

CD7 — ""Antigens, CD7"" following the same pattern. The abstract mentions CD7-directed CAR T cells as prior approach.

**Technology/Methodology:**
CRISPR/Cas9 — ""CRISPR-Cas Systems"" is the MeSH heading.

Gene knockout — ""Gene Knockout Techniques"" is the MeSH term.

Let me also consider whether I need ""Fratricide"" — that's not a MeSH term.

Should I include ""Neoplasms, T-Cell"" as a broader term? It might be redundant with the specific disease terms already listed.

Let me also think about whether ""Gene Editing"" should be included — it's related but ""Gene Knockout Techniques"" is more specific to what they did.

I think I should organize these logically by category for clarity.

Let me compile the final list:

Disease terms:
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, T-Cell

Therapeutic/Cellular terms:
- Receptors, Chimeric Antigen
- Immunotherapy, Adoptive
- T-Lymphocytes
- Antigens, CD28
- Antigens, CD7

Methodology:
- CRISPR-Cas Systems
- Gene Knockout Techniques

Wait — I should reconsider ""Antigens, CD28"" vs ""CD28 Antigens."" Looking at MeSH conventions more carefully, the heading is ""Antigens, CD28."" I'll go with that.

Actually, let me reconsider whether to include ""Antigens, CD7."" The study mentions CD7-directed CAR T cells as background context, not as the primary focus. However, it's discussed as part of the rationale and as a comparison point. I think including it is reasonable since it's part of the research landscape being addressed.

I should also consider ""Cell Line, Tumor"" — the abstract mentions testing against T-ALL, which likely involves cell lines, but the abstract doesn't explicitly mention cell lines. I'll leave it out unless there's clear evidence.

Let me finalize my list and present it clearly.","Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD2","Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD2","# Constraints
The question you must answer is from a science domain. You are a senior biomedical librarian and immunology researcher specializing in hematologic malignancies and CAR-T cell therapy. With a PhD in Molecular Biology and 15 years of experience indexing oncology studies for PubMed, you possess encyclopedic knowledge of the MeSH taxonomy. Your precise expertise allows you to instantly map complex genetic targeting strategies to their correct standardized medical subject headings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis.,"Analyze the provided biomedical study text and summarize its main finding in exactly one sentence.

### Input Text
**Title:** Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions.
**Abstract:** The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis. Despite being affected in Crohn's disease and serving as a major target for a range of infections, we know relatively little about the complexity of cellular responses and cell-cell communication in the ileum during infection. Here we present GutPath, an atlas of over 500,000 single cells with RNA and protein expression profiles for 91 cell states in the ileum across diverse infectious archetypes. We show that GutPath accurately captures established immune responses to infection while revealing pathogen-specific responses in enterocytes. To highlight the discovery potential of this atlas, we identify a new enterocyte transcriptional state present during Yersinia pseudotuberculosis infection that is spatially linked to bacterial load and tissue pathology. GutPath establishes a much-needed resource for the immunology community that will accelerate the study of transcriptional diversity in the cellular landscapes of the small intestine.

### Constraints
- **Length:** The output must be a single sentence.
- **Focus:** Capture the primary discovery or contribution of the study.
- **Clarity:** Ensure the sentence is grammatically correct and concise.","This study introduces GutPath, a comprehensive single-cell atlas of the ileum across diverse infections, revealing that pathogens transcriptionally reprogram the intestinal epithelium and epithelial-immune interactions while identifying a novel enterocyte state linked to Yersinia pseudotuberculosis pathology.","Okay, I need to analyze this biomedical study abstract and distill it into exactly one sentence that captures the primary finding or contribution. Let me break down what's in this abstract.

The title already tells me a lot: diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions. That's a core finding right there — infections cause transcriptional changes in the gut epithelium and alter how epithelial cells communicate with immune cells.

Now looking at the abstract itself. The distal small intestine (ileum) is important for nutrient and fluid homeostasis, is affected in Crohn's disease, and is a target for infections, but we don't know much about cellular responses there during infection. That's the gap.

Their contribution: they created GutPath, an atlas of over 500,000 single cells with RNA and protein expression profiles, covering 91 cell states in the ileum across diverse infectious archetypes. So this is a single-cell resource — that's a major contribution in and of itself.

What did they find with it? GutPath captures established immune responses to infection (validating the resource) AND reveals pathogen-specific responses in enterocytes. So enterocytes — the absorptive cells of the intestine — show pathogen-specific transcriptional changes. That's a key finding.

They also highlight a specific discovery: a new enterocyte transcriptional state during Yersinia pseudotuberculosis infection that's spatially linked to bacterial load and tissue pathology. This is an example of the discovery potential of their atlas.

The abstract closes by saying GutPath is a resource for the immunology community to study transcriptional diversity in the small intestine's cellular landscapes.

So what's the main finding/contribution? There are two layers here:
1. The resource itself — GutPath, a comprehensive single-cell atlas
2. The biological insight — infections reprogram the intestinal epithelium and epithelial-immune interactions, with pathogen-specific enterocyte responses

I need to capture both in one sentence. Let me think about how to structure this.

The sentence should mention:
- GutPath as a single-cell atlas of the ileum across infections
- The key finding about transcriptional reprogramming of epithelium and epithelial-immune interactions
- Ideally the novel enterocyte state discovery as an example

Let me draft something:

""This study introduces GutPath, a comprehensive single-cell atlas of the ileum across diverse infections, revealing that pathogens transcriptionally reprogram the intestinal epithelium and epithelial-immune interactions while identifying a novel enterocyte state linked to Yersinia pseudotuberculosis pathology.""

Let me check this. It's one sentence. It mentions the resource (GutPath, single-cell atlas, ileum, diverse infections). It captures the main finding (transcriptional reprogramming of epithelium and epithelial-immune interactions). It includes the specific discovery (novel enterocyte state linked to Yersinia pathology). It's grammatically correct and reasonably concise.

Could I make it tighter? I could drop the Yersinia part, but including it actually demonstrates the discovery potential of the atlas, which seems like an important aspect of the contribution. I think including it adds specificity and shows what the atlas can do.

Is there anything I'm missing? The abstract mentions 500,000 cells and 91 cell states — should I include those numbers? They add detail but might make the sentence too long. I think ""comprehensive"" conveys the scale without needing exact numbers. Let me keep it as is.

One more check — the sentence flows well: ""This study introduces GutPath... revealing that... while identifying..."" The structure moves from the resource to the broad finding to the specific discovery. That's logical and readable.

I'm satisfied with this sentence. It captures the primary contribution (the atlas), the main biological finding (transcriptional reprogramming), and a concrete discovery example (novel enterocyte state), all in one grammatically correct sentence.","Title: Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions. | Abstract: The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis. Despite being affected in Crohn's disease and serving as a major target for a range of infections, we know relatively little about the complexity of cellular responses and cell-cell communication in the ileum during infection. Here we present GutPath, an atlas of over 500,000 single cells with RNA and protein expression profiles for 91 cell states in the ileum across diverse infectious archetypes. We show that GutPath accurately captures established immune responses to infection while revealing pathogen-specific responses in enterocytes. To highlight the discovery potential of this atlas, we identify a new enterocyte transcriptional state present during Yersinia pseudotuberculosis infection that is spatially linked to bacterial load and tissue pathology. GutPath establishes a much-needed resource for the immunology community that will accelerate the study of transcriptional diversity in the cellular landscapes of the small intestine.","Title: Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions. | Abstract: The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis. Despite being affected in Crohn's disease and serving as a major target for a range of infections, we know relatively little about the complexity of cellular responses and cell-cell communication in the ileum during infection. Here we present GutPath, an atlas of over 500,000 single cells with RNA and protein expression profiles for 91 cell states in the ileum across diverse infectious archetypes. We show that GutPath accurately captures established immune responses to infection while revealing pathogen-specific responses in enterocytes. To highlight the discovery potential of this atlas, we identify a new enterocyte transcriptional state present during Yersinia pseudotuberculosis infection that is spatially linked to bacterial load and tissue pathology. GutPath establishes a much-needed resource for the immunology community that will accelerate the study of transcriptional diversity in the cellular landscapes of the small intestine.","# Constraints
The question you must answer is from a science domain. You are a senior computational immunologist and principal investigator specializing in single-cell genomics of the gut. With over 15 years of experience analyzing host-pathogen interactions, you possess deep expertise in transcriptional reprogramming and epithelial-immune crosstalk. Your rigorous academic background makes you the ideal expert to distill complex biomedical findings into precise summaries. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors.,"### Task
Summarize the principal finding of the provided biomedical study abstract into a single, concise sentence.

### Input Data
**Title:** Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting.
**Abstract:** Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor effects and cytokine-mediated toxicities. The American Society for Clinical Oncology (ASCO) Annual Meeting is a key platform for the presentation of cutting-edge clinical data, and in this brief correspondence, we summarize the principal early-phase clinical trials with CAR-T and TCR-T for solid tumors reported at the 2026 meeting.

### Constraints
- **Length:** Exactly one sentence.
- **Focus:** Capture the main conclusion or primary update regarding clinical trials presented at the 2026 meeting.
- **Accuracy:** Maintain the original meaning and tone; do not add external information.","This correspondence reviews the principal early-phase clinical trials for CAR-T and TCR-T therapies in solid tumors presented at the 2026 ASCO Annual Meeting, while noting that their application continues to be limited by antigen heterogeneity, immunosuppressive tumor microenvironments, manufacturing complexity, and safety concerns.","Alright, let me read through this abstract carefully. The title tells me this is about updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. So the core subject is already clear — it's a summary of what was presented at ASCO 2026 regarding these adoptive cellular therapies in solid tumors.

Now let me go through the abstract itself. It starts by establishing context — ACT has reshaped hematologic malignancies and is now being explored in solid tumors. That's background. Then it distinguishes CAR-T (targets surface antigens, HLA-independent) from TCR-T (recognizes intracellular antigens via MHC). Also background context, useful for understanding the two modalities but probably not the main finding itself.

Then the abstract identifies the key challenges: antigen heterogeneity, immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns (on-target/off-tumor effects, cytokine-mediated toxicities). These are important limitations that frame why solid tumor applications remain difficult.

The final sentence is the real ""what is this paper doing"" statement — it says this correspondence summarizes the principal early-phase clinical trials with CAR-T and TCR-T for solid tumors reported at the 2026 ASCO meeting.

So what's the principal finding here? This is actually a correspondence/summary piece. The ""finding"" is essentially that they're reviewing early-phase clinical trials presented at ASCO 2026, while acknowledging the ongoing challenges. The abstract doesn't present a single clinical result — it's a review summary. So I need to capture: what the correspondence does (reviews early-phase trials of CAR-T and TCR-T in solid tumors from ASCO 2026) and the framing that these applications remain limited by specific challenges.

Let me think about what to include and what to cut. The constraints say to capture the main conclusion or primary update. The main update is the summary of early-phase clinical trials at ASCO 2026. But the persistent limitations are also a key part of the picture — they contextualize why this matters. I should mention both the review of trials and the ongoing challenges, but concisely.

Let me draft something: ""This correspondence reviews the principal early-phase clinical trials of CAR-T and TCR-T therapies in solid tumors presented at the 2026 ASCO Annual Meeting, while noting that their application continues to be limited by antigen heterogeneity, immunosuppressive tumor microenvironments, manufacturing complexity, and safety concerns.""

Let me check — is this one sentence? Yes. Does it capture the main point? I think so — it covers both what the correspondence does (reviews trials) and the key limitations that frame the field. Does it add external information? No, everything is from the abstract. Is the tone preserved? I believe so — it's measured and academic.

Could I make it shorter? I could drop the specific limitations and just say ""remains limited by significant challenges,"" but that loses important detail. The abstract specifically enumerates these barriers, and as someone who works in this field, I know these are the central issues — antigen heterogeneity, TME, manufacturing, safety. Including them makes the summary more informative and faithful to the source.

I think this is solid. Let me do one final check on sentence structure to make sure it reads cleanly as a single sentence without being a run-on... The structure is ""This correspondence reviews X, while noting Y."" That's grammatically sound — a main clause with a subordinate clause. Good.","Title: Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. | Abstract: Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor effects and cytokine-mediated toxicities. The American Society for Clinical Oncology (ASCO) Annual Meeting is a key platform for the presentation of cutting-edge clinical data, and in this brief correspondence, we summarize the principal early-phase clinical trials with CAR-T and TCR-T for solid tumors reported at the 2026 meeting.","Title: Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. | Abstract: Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor effects and cytokine-mediated toxicities. The American Society for Clinical Oncology (ASCO) Annual Meeting is a key platform for the presentation of cutting-edge clinical data, and in this brief correspondence, we summarize the principal early-phase clinical trials with CAR-T and TCR-T for solid tumors reported at the 2026 meeting.","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and translational researcher specializing in adoptive cellular therapies, currently based at a leading NCI-designated cancer center. With over 15 years of experience in CAR-T and TCR-T clinical trials, you regularly attend ASCO to interpret cutting-edge data for solid tumor applications. Your expertise bridges complex immunology with practical patient care, making you ideal for summarizing high-level biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process.","# Task: Summarize Biomedical Study Finding

## Instructions
Analyze the provided biomedical study text below and summarize its **main finding** in exactly **one sentence**.

## Constraints
- **Length**: Strictly one sentence.
- **Focus**: Identify the primary discovery regarding the relationship between specific T cells and lung cancer progression.
- **Clarity**: Ensure the sentence is grammatically complete and clearly states the causal or correlational link found in the study.

## Input Text
Title: A preinvasive regulatory T cell axis for lung cancer interception. | Abstract: Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis2,3. Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development. Here we explore how the T cell network is remodelled during NSCLC development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions surveilled by autofluorescence bronchoscopy and computed tomography (CT) imaging. Effector regulatory CD4+ T cells (eTreg cells) expressing basic leucine zipper ATF-like transcription factor (BATF) accumulated in high-grade premalignant airway lesions and were clonally related to circulating eTreg cells. Circulating eTreg cells were increasingly elevated during preinvasive progression, enabling lung tumorigenesis to be tracked through analysis of peripheral blood. Emergence of this clonally coordinated eTreg cell circuit defined rapid progression in patients with early-stage NSCLC detected during CT screening. In mice, carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eTreg cell axis across the blood, airways and draining lymph nodes (dLNs). This culminated in an expansion of lung BATF+ Treg cells and ","The study identifies a clonally coordinated axis of BATF-expressing effector regulatory CD4+ T cells (eTregs) that accumulates in high-grade premalignant airway lesions and becomes elevated in peripheral blood, thereby defining rapid progression during early-stage non-small cell lung cancer development.","Alright, I need to summarize the main finding of this biomedical study in exactly one sentence. Let me break down what I'm reading here.

The study is about lung cancer, specifically non-small cell lung cancer (NSCLC), and it's focusing on early detection and intervention. The key question is about the relationship between specific T cells and lung cancer progression.

Let me parse the abstract carefully. They used multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions. The main discovery seems to be about effector regulatory CD4+ T cells — eTreg cells — that express BATF. These cells accumulate in high-grade premalignant airway lesions. Importantly, they're clonally related to circulating eTreg cells in the blood.

So there's a connection between what's happening in the tissue and what's detectable in peripheral blood. The circulating eTreg cells increase during preinvasive progression, which means you could potentially track lung tumorigenesis through blood analysis. That's clinically significant.

The emergence of this ""clonally coordinated eTreg cell circuit"" defines rapid progression in early-stage NSCLC patients detected during CT screening. They also validated this in mice — carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eTreg cell axis across blood, airways, and draining lymph nodes.

So the core finding is about this BATF-expressing eTreg axis that: (1) accumulates in premalignant lesions, (2) is detectable in blood, (3) defines rapid progression. The causal or correlational link is that this eTreg cell circuit is associated with — and seemingly enables — lung cancer progression at its preinvasive stages.

Now I need to capture this in one grammatically complete sentence. I should focus on the primary discovery: the relationship between these specific T cells and lung cancer progression.

Let me draft this:

""The study identifies a clonally coordinated axis of BATF-expressing effector regulatory CD4+ T cells (eTregs) that accumulates in high-grade premalignant airway lesions and becomes elevated in peripheral blood, thereby defining rapid progression during early-stage non-small cell lung cancer development.""

Let me check: Is it one sentence? Yes. Does it state the main finding? Yes — it identifies the eTreg axis, where these cells accumulate, the blood-based detection aspect, and the link to rapid progression. Is it grammatically complete? Yes. Does it capture the causal/correlational link? Yes — the ""thereby defining"" clause connects the eTreg axis to rapid progression.

I think this works. It's precise, includes the key molecular details (BATF, eTregs, CD4+), mentions both the tissue and blood compartments, and connects to clinical progression. The sentence doesn't overstate causality — it says ""defining"" rather than ""causing,"" which aligns with the study's language about the eTreg circuit defining rapid progression.","Title: A preinvasive regulatory T cell axis for lung cancer interception. | Abstract: Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis2,3. Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development. Here we explore how the T cell network is remodelled during NSCLC development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions surveilled by autofluorescence bronchoscopy and computed tomography (CT) imaging. Effector regulatory CD4+ T cells (eTreg cells) expressing basic leucine zipper ATF-like transcription factor (BATF) accumulated in high-grade premalignant airway lesions and were clonally related to circulating eTreg cells. Circulating eTreg cells were increasingly elevated during preinvasive progression, enabling lung tumorigenesis to be tracked through analysis of peripheral blood. Emergence of this clonally coordinated eTreg cell circuit defined rapid progression in patients with early-stage NSCLC detected during CT screening. In mice, carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eTreg cell axis across the blood, airways and draining lymph nodes (dLNs). This culminated in an expansion of lung BATF+ Treg cells and ","Title: A preinvasive regulatory T cell axis for lung cancer interception. | Abstract: Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis2,3. Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development. Here we explore how the T cell network is remodelled during NSCLC development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions surveilled by autofluorescence bronchoscopy and computed tomography (CT) imaging. Effector regulatory CD4+ T cells (eTreg cells) expressing basic leucine zipper ATF-like transcription factor (BATF) accumulated in high-grade premalignant airway lesions and were clonally related to circulating eTreg cells. Circulating eTreg cells were increasingly elevated during preinvasive progression, enabling lung tumorigenesis to be tracked through analysis of peripheral blood. Emergence of this clonally coordinated eTreg cell circuit defined rapid progression in patients with early-stage NSCLC detected during CT screening. In mice, carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eTreg cell axis across the blood, airways and draining lymph nodes (dLNs). This culminated in an expansion of lung BATF+ Treg cells and ","# Constraints
The question you must answer is from a science domain. You are a senior translational oncologist and immunologist with 20 years of experience specializing in early-stage lung cancer detection. Based in a leading research hospital, you expertly interpret multi-omic profiling data to bridge laboratory findings with clinical applications for preinvasive lesions. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI).,"### Task
Summarize the main finding of the provided biomedical study abstract in exactly one sentence.

### Input Data
**Title:** [Myositis induced by immune checkpoint inhibitor therapy]

**Abstract:** Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI). As a distinct type of rheumatic immune-related adverse events (irAE), it presents challenges in terms of diagnosis and patient management. The high mortality and the potential for rapid progression necessitates prompt treatment. This article provides a practice-oriented overview of myositis-induced irAEs, focusing on the diagnostic and treatment management and the prognostic implications. A selective literature review was conducted, covering current studies, registry data and pharmacovigilance data as well as guidelines for recognizing and treating ICI-associated myositis irAEs. Myositis-induced irAEs typically manifest within 1 month of initiating ICI therapy. The incidence is between 0.5% and 1%; however, it is significantly higher with ICI combination therapies. In around half of the cases, myositis is the only irAE manifestation. The number of cases of neuromuscular irAE overlap with myocarditis and/or myasthenia rose from 3.7% before to 8.3% after 2017. Around 20% of cases of isolated myositis require ventilation, compared to 50-80% of cases of overlap syndrome, which is associated with a high mortality of 40%. If a myositis-irAE is suspected, high-dose glucocorticoid therapy should be initiated immediately. The treatment often includes glucocorticoid-spar

### Constraints
- **Length:** Strictly one sentence.
- **Focus:** Capture the primary clinical finding or conclusion.
- **Tone:** Professional and objective.
- **Vocabulary:** Use standard medical terminology; ensure clarity for a clinical audience.","Immune checkpoint inhibitor-induced myositis is a severe, early-onset adverse event that requires immediate high-dose glucocorticoid therapy upon suspicion, with overlap syndromes involving myocarditis or myasthenia gravis conferring significantly higher rates of mechanical ventilation and a 40% mortality rate.","Alright, I need to summarize this abstract in exactly one sentence. Let me break down what's important here.

The abstract is about myositis caused by immune checkpoint inhibitors (ICI). Key points I'm picking up: it's a severe side effect, happens usually within 1 month of starting ICI therapy, incidence is 0.5-1% but higher with combination therapies. The really critical clinical findings seem to be about overlap syndromes — when myositis overlaps with myocarditis or myasthenia, the numbers get much worse. Isolated myositis: 20% need ventilation. Overlap syndrome: 50-80% need ventilation, and mortality jumps to 40%. That's a striking finding.

Treatment-wise: high-dose glucocorticoids immediately upon suspicion. That's the management recommendation.

So what's the ""main finding""? The abstract is a review article, so the main finding is really a synthesis. The most clinically actionable and striking points are: early onset, need for immediate treatment, and the dramatically worse prognosis with overlap syndromes.

Let me think about what to emphasize. The mortality data and ventilation rates for overlap syndromes are probably the most important clinical takeaway. But the treatment recommendation is also critical.

Let me draft something:

""Immune checkpoint inhibitor-induced myositis is a severe, early-onset adverse event requiring immediate high-dose glucocorticoid therapy upon suspicion, with overlap syndromes involving myocarditis or myasthenia gravis associated with significantly higher ventilation rates and 40% mortality.""

That captures: what it is (severe irAE), when it happens (early-onset), what to do (immediate glucocorticoids), and the key prognostic finding (overlap syndromes are much worse with 40% mortality).

Let me check — is this one sentence? Yes. Is it professional and using standard medical terminology? Yes. Does it capture the primary clinical finding? I think so — it hits the treatment recommendation and the prognostic data, which seem to be the most clinically significant points.

I could also focus more on incidence, but that feels less like the ""main finding"" and more like background. The real clinical punch is the overlap syndrome mortality and the need for immediate treatment.

I think my draft works well. Let me refine slightly for flow.","Title: [Myositis induced by immune checkpoint inhibitor therapy]. | Abstract: Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI). As a distinct type of rheumatic immune-related adverse events (irAE), it presents challenges in terms of diagnosis and patient management. The high mortality and the potential for rapid progression necessitates prompt treatment. This article provides a practice-oriented overview of myositis-induced irAEs, focusing on the diagnostic and treatment management and the prognostic implications. A selective literature review was conducted, covering current studies, registry data and pharmacovigilance data as well as guidelines for recognizing and treating ICI-associated myositis irAEs. Myositis-induced irAEs typically manifest within 1 month of initiating ICI therapy. The incidence is between 0.5% and 1%; however, it is significantly higher with ICI combination therapies. In around half of the cases, myositis is the only irAE manifestation. The number of cases of neuromuscular irAE overlap with myocarditis and/or myasthenia rose from 3.7% before to 8.3% after 2017. Around 20% of cases of isolated myositis require ventilation, compared to 50-80% of cases of overlap syndrome, which is associated with a high mortality of 40%. If a myositis-irAE is suspected, high-dose glucocorticoid therapy should be initiated immediately. The treatment often includes glucocorticoid-spar","Title: [Myositis induced by immune checkpoint inhibitor therapy]. | Abstract: Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI). As a distinct type of rheumatic immune-related adverse events (irAE), it presents challenges in terms of diagnosis and patient management. The high mortality and the potential for rapid progression necessitates prompt treatment. This article provides a practice-oriented overview of myositis-induced irAEs, focusing on the diagnostic and treatment management and the prognostic implications. A selective literature review was conducted, covering current studies, registry data and pharmacovigilance data as well as guidelines for recognizing and treating ICI-associated myositis irAEs. Myositis-induced irAEs typically manifest within 1 month of initiating ICI therapy. The incidence is between 0.5% and 1%; however, it is significantly higher with ICI combination therapies. In around half of the cases, myositis is the only irAE manifestation. The number of cases of neuromuscular irAE overlap with myocarditis and/or myasthenia rose from 3.7% before to 8.3% after 2017. Around 20% of cases of isolated myositis require ventilation, compared to 50-80% of cases of overlap syndrome, which is associated with a high mortality of 40%. If a myositis-irAE is suspected, high-dose glucocorticoid therapy should be initiated immediately. The treatment often includes glucocorticoid-spar","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and rheumatologist specializing in immune-related adverse events from cancer therapies. With 20 years of clinical experience and active involvement in global pharmacovigilance registries, you possess unparalleled expertise in diagnosing and managing ICI-induced myositis. Your deep understanding of current guidelines and rapid treatment protocols makes you the ideal authority for summarizing these critical biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | mRNA Vaccines | Bioengineering | Animals | RNA, Messenger | Immunity, Innate","Extract and list the Medical Subject Headings (MeSH) terms that best index the study described below. MeSH terms are a controlled vocabulary thesaurus used for indexing articles in the life sciences.

### Study Content
**Title:** Bioengineering strategies for improving the immunogenicity of mRNA vaccines.
**Abstract:** Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distr","Based on the provided title and abstract, the following MeSH terms best index this study:

*   **RNA, Messenger**
*   **mRNA Vaccines**
*   **Immunogenicity, Vaccine**
*   **Biomedical Engineering**
*   **Genetic Engineering**
*   **Drug Delivery Systems**
*   **Immunity, Innate**
*   **Immunity, Cellular**
*   **Immunity, Humoral**
*   **Intracellular Transport**
*   **Tissue Distribution**
*   **Immunotherapy**
*   **Neoplasms**
*   **Communicable Diseases**
*   **Humans**
*   **Animals**","Okay, let me look at this prompt. I need to extract MeSH terms that best index a study about mRNA vaccine bioengineering and immunogenicity.

Let me break down the title and abstract carefully. The title mentions ""Bioengineering strategies for improving the immunogenicity of mRNA vaccines."" So right away, I'm seeing several core concepts: bioengineering, immunogenicity, and mRNA vaccines.

Starting with the most obvious MeSH terms... ""RNA, Messenger"" is a standard MeSH heading — that's straightforward since the study is fundamentally about mRNA. Then ""mRNA Vaccines"" — let me think, is that an actual MeSH term? I believe ""RNA Vaccines"" is the MeSH heading, but given the study specifically discusses mRNA vaccines... Actually, I should include ""mRNA Vaccines"" as it's commonly used and may be an entry term or subheading. Let me think about this more carefully. The MeSH hierarchy has ""RNA Vaccines"" under ""Vaccines,"" and mRNA vaccines would fall there. I'll list it as ""mRNA Vaccines"" since that's the most precise indexing.

Now, ""immunogenicity"" — the MeSH term would be ""Immunogenicity, Vaccine"" which captures the concept of vaccine-induced immune response. That's directly from the title.

""Bioengineering"" — the MeSH heading is ""Biomedical Engineering"" or possibly ""Genetic Engineering"" since they're talking about engineering RNA architecture. Both seem relevant. The title says ""bioengineering strategies"" which maps to ""Biomedical Engineering,"" and the manipulation of RNA structure and delivery systems suggests ""Genetic Engineering"" as well.

The abstract mentions ""delivery systems"" — ""Drug Delivery Systems"" is a MeSH term that would apply here since they're discussing how RNA is delivered and how delivery systems regulate innate sensing and trafficking.

Speaking of which — ""innate sensing"" maps to ""Immunity, Innate."" The abstract mentions ""humoral and cellular immunity"" so I need ""Immunity, Cellular"" and ""Immunity, Humoral"" as well. These are all standard MeSH headings.

""Intracellular trafficking"" — the MeSH term would be ""Intracellular Transport"" — that's a direct match.

""Tissue distribution"" — there's actually a MeSH term ""Tissue Distribution"" that I should include since it's explicitly mentioned in the abstract.

The abstract mentions several disease areas: infectious diseases, cancer immunotherapy, cardiovascular, neurodegenerative, autoimmune, and metabolic disorders. For MeSH indexing, I should capture the major therapeutic areas. ""Communicable Diseases"" covers infectious diseases. ""Neoplasms"" is the MeSH term for cancer. ""Immunotherapy"" is relevant since cancer immunotherapy is mentioned.

Should I include specific disease terms for cardiovascular, neurodegenerative, autoimmune, and metabolic disorders? The abstract mentions them as expansion targets but the study's focus is really on the vaccine platform technology, not on these specific diseases per se. I think including the broad categories is appropriate but I shouldn't over-index on diseases that are merely mentioned as potential applications. Let me include ""Neoplasms"" and ""Communicable Diseases"" as they seem to be the primary current applications discussed.

For check tags — standard MeSH indexing practice includes ""Humans"" and ""Animals"" when applicable. The abstract mentions clinical success and preclinical concepts like tissue distribution studies, which typically involve both human and animal research. These are standard check tags I should include.

Let me also consider whether ""Vaccination"" or ""Vaccines"" should be included. The study is about vaccines broadly, but ""mRNA Vaccines"" already captures this. I don't think I need the broader term unless the study discusses vaccination as a public health intervention, which it doesn't seem to.

What about ""Antigens""? The abstract mentions ""antigen design"" and ""antigen output."" There's a MeSH term ""Antigens"" but it might be too broad. The study is really about the vaccine platform and delivery, not antigen characterization per se. I'll leave it out.

""Molecular Biology"" could be relevant given the RNA architecture discussion, but it's quite broad. The more specific terms like ""RNA, Messenger"" and ""Genetic Engineering"" already capture this aspect.

Let me also think about whether ""Nanoparticles"" or ""Lipid Nanoparticles"" should be included. The abstract mentions ""delivery systems"" but doesn't specifically name lipid nanoparticles. While mRNA vaccines typically use lipid nanoparticles, I should stick to what's explicitly stated or strongly implied. ""Drug Delivery Systems"" captures this concept adequately.

Reviewing my list now... I think I have a solid set of MeSH terms that covers:
- The core subject (RNA, Messenger; mRNA Vaccines)
- The engineering aspect (Biomedical Engineering; Genetic Engineering; Drug Delivery Systems)
- The immunological concepts (Immunogenicity, Vaccine; Immunity, Innate; Immunity, Cellular; Immunity, Humoral; Immunotherapy)
- The biological processes (Intracellular Transport; Tissue Distribution)
- Disease applications (Neoplasms; Communicable Diseases)
- Standard check tags (Humans; Animals)

This looks comprehensive and accurately reflects the study content without over-indexing on tangential mentions.","Title: Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Abstract: Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distr","Title: Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Abstract: Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distr","# Constraints
The question you must answer is from a science domain. You are a senior biomedical librarian and immunology researcher specializing in mRNA vaccine bioengineering. With a PhD in Molecular Biology and 15 years of experience indexing clinical trials for the National Library of Medicine, you possess encyclopedic knowledge of MeSH terminology and vaccine architecture. Your precise expertise ensures accurate mapping of complex immunogenicity strategies to standardized medical subject headings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress.","### Task
Summarize the main finding of the provided biomedical study abstract into a single, concise sentence.

### Constraints
- **Length**: Exactly one sentence.
- **Focus**: Highlight the primary mechanism and outcome.
- **Content**: Use only the information provided in the text below.

### Input Text
**Title**: Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy.

**Abstract**: Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress. Pyroptosis, a highly immunogenic form of programmed cell death that can be activated through mechanisms not strictly dependent on exogenous reactive oxygen species (ROS), offers a promising alternative for immune activation but remains challenging to induce effectively in vivo. Here, we report an inhalable fluorinated polymer nanoplatform (PFAP) that triggers mitochondrial dysfunction to initiate pyroptosis and thereby elicits potent antitumor immunity in the lung. PFAP integrates perfluoroalkyl segments with cationic domains to enhance interactions with mitochondrial membranes, while a detachable polyethylene glycol shell preserves nanoparticle stability during aerosolization and facilitates penetration of pulmonary barriers. Upon exposure to the acidic TME, PFAP restores membrane-disruptive activity, leading to mitochondrial depolarization, Cyto C release, caspase-3 activation, GSDME cleavage, and pyroptosis induction. In orthotopic and metastatic lung cancer models, inhaled PFAP achieves efficient lung delivery, elicits robust antitumor immunity, and suppresses tumor progression without detectable systemic toxicity. This work","An inhalable fluorinated polymer nanoplatform (PFAP) triggers mitochondrial dysfunction to induce GSDME-mediated pyroptosis within the acidic tumor microenvironment, thereby eliciting robust antitumor immunity and suppressing lung tumor progression without detectable systemic toxicity.","Okay, let me parse this prompt carefully. I need to summarize a biomedical study abstract into exactly one sentence, focusing on the primary mechanism and outcome, using only the information in the text.

Let me read through the abstract to identify the key elements.

The title tells me it's about an ""Inhaled Fluorinated Polymer"" that ""Triggers Pyroptosis for Lung Cancer Immunotherapy."" So the core intervention is an inhaled fluorinated polymer, and the goal is lung cancer immunotherapy via pyroptosis.

Now the abstract... Lung cancer has high mortality, immunotherapy is limited by immunosuppressive TME and oxidative stress buffering. Pyroptosis is presented as an alternative—immunogenic cell death that doesn't strictly depend on exogenous ROS, but it's hard to induce in vivo.

The ""Here, we report"" section is where the main finding is. They developed PFAP—an inhalable fluorinated polymer nanoplatform. What does it do? It ""triggers mitochondrial dysfunction to initiate pyroptosis and thereby elicits potent antitumor immunity in the lung.""

So the mechanism is: PFAP causes mitochondrial dysfunction → pyroptosis → antitumor immunity.

How does PFAP work structurally? Perfluoroalkyl segments + cationic domains enhance mitochondrial membrane interactions. PEG shell for stability and pulmonary barrier penetration. In acidic TME, PFAP restores membrane-disruptive activity → mitochondrial depolarization → Cyto C release → caspase-3 activation → GSDME cleavage → pyroptosis.

The in vivo results: inhaled PFAP achieves lung delivery, elicits antitumor immunity, suppresses tumor progression, no systemic toxicity.

Now I need to distill this into ONE sentence. The primary mechanism is mitochondrial dysfunction leading to pyroptosis. The outcome is antitumor immunity and tumor suppression.

Let me think about what's essential:
- The intervention: inhalable fluorinated polymer (PFAP)
- The mechanism: triggers mitochondrial dysfunction → pyroptosis (specifically GSDME-mediated, since that's the final step mentioned)
- The outcome: antitumor immunity, tumor suppression, no systemic toxicity

The acidic TME trigger is important context for HOW it works—PFAP is activated in acidic TME. Should I include that? It adds mechanistic detail. The prompt says ""primary mechanism and outcome."" The acidic TME activation is part of the mechanism, but the core mechanism is mitochondrial dysfunction → pyroptosis.

Hmm, but one sentence is tight. Let me think about what to prioritize. The most novel finding is that this inhalable polymer triggers mitochondrial dysfunction-mediated pyroptosis for antitumor immunity. The ""no systemic toxicity"" is an important outcome too—it addresses a key concern.

Let me try drafting:

""An inhalable fluorinated polymer nanoplatform (PFAP) triggers mitochondrial dysfunction to induce GSDME-mediated pyroptosis, thereby eliciting robust antitumor immunity and suppressing lung tumor progression without detectable systemic toxicity.""

Let me check: Does this capture the primary mechanism? Yes—mitochondrial dysfunction → GSDME-mediated pyroptosis. Does it capture the outcome? Yes—antitumor immunity, tumor suppression, no toxicity. Is it one sentence? Yes. Is it only from the text? Let me verify... ""inhalable fluorinated polymer nanoplatform (PFAP)""—yes. ""triggers mitochondrial dysfunction""—yes, direct quote essentially. ""induce... pyroptosis""—yes. ""GSDME-mediated""—the abstract mentions ""GSDME cleavage"" as part of the pyroptosis induction, so GSDME-mediated is a fair characterization. ""eliciting robust antitumor immunity""—yes. ""suppressing... tumor progression""—yes. ""without detectable systemic toxicity""—yes.

Should I mention the acidic TME? It's part of the mechanism—PFAP restores activity in acidic TME. But including it might make the sentence unwieldy. The core finding is the mitochondrial dysfunction → pyroptosis pathway. The acidic TME is more about the trigger/activation condition. I think I can leave it out for conciseness, or... actually, it might be worth noting because it shows the selectivity—PFAP is activated specifically in the TME. That's an important mechanistic feature.

Let me try with it:

""An inhalable fluorinated polymer nanoplatform (PFAP) triggers mitochondrial dysfunction to induce GSDME-mediated pyroptosis within the acidic tumor microenvironment, thereby eliciting robust antitumor immunity and suppressing lung tumor progression without detectable systemic toxicity.""

That's still one sentence. It adds the TME specificity, which is mechanistically important—it shows the nanoplatform is designed to activate in the tumor environment. I think this is better. It captures the intervention, the mechanistic pathway (mitochondrial dysfunction → GSDME-mediated pyroptosis), the activation context (acidic TME), and the outcomes (immunity, tumor suppression, no toxicity).

Wait, let me reconsider—is ""GSDME-mediated"" too specific? The abstract lists a cascade: mitochondrial depolarization → Cyto C release → caspase-3 activation → GSDME cleavage → pyroptosis. GSDME cleavage is the final executor of pyroptosis in this cascade. Calling it ""GSDME-mediated pyroptosis"" is accurate and concise—it captures the specific pyroptosis pathway without listing every intermediate. I think that's appropriate.

Actually, the prompt says ""primary mechanism."" The primary mechanism is mitochondrial dysfunction leading to pyroptosis. GSDME is the specific mediator. Including ""GSDME-mediated"" adds precision without being excessive. I'll keep it.

Let me re-read my sentence one more time for flow and accuracy:

""An inhalable fluorinated polymer nanoplatform (PFAP) triggers mitochondrial dysfunction to induce GSDME-mediated pyroptosis within the acidic tumor microenvironment, thereby eliciting robust antitumor immunity and suppressing lung tumor progression without detectable systemic toxicity.""

This reads well. It's one sentence. It captures the intervention (PFAP), the mechanism (mitochondrial dysfunction → GSDME-mediated pyroptosis in acidic TME), and the outcomes (antitumor immunity, tumor suppression, no systemic toxicity). All information is from the abstract. I'm satisfied with this.","Title: Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy. | Abstract: Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress. Pyroptosis, a highly immunogenic form of programmed cell death that can be activated through mechanisms not strictly dependent on exogenous reactive oxygen species (ROS), offers a promising alternative for immune activation but remains challenging to induce effectively in vivo. Here, we report an inhalable fluorinated polymer nanoplatform (PFAP) that triggers mitochondrial dysfunction to initiate pyroptosis and thereby elicits potent antitumor immunity in the lung. PFAP integrates perfluoroalkyl segments with cationic domains to enhance interactions with mitochondrial membranes, while a detachable polyethylene glycol shell preserves nanoparticle stability during aerosolization and facilitates penetration of pulmonary barriers. Upon exposure to the acidic TME, PFAP restores membrane-disruptive activity, leading to mitochondrial depolarization, Cyto C release, caspase-3 activation, GSDME cleavage, and pyroptosis induction. In orthotopic and metastatic lung cancer models, inhaled PFAP achieves efficient lung delivery, elicits robust antitumor immunity, and suppresses tumor progression without detectable systemic toxicity. This work","Title: Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy. | Abstract: Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress. Pyroptosis, a highly immunogenic form of programmed cell death that can be activated through mechanisms not strictly dependent on exogenous reactive oxygen species (ROS), offers a promising alternative for immune activation but remains challenging to induce effectively in vivo. Here, we report an inhalable fluorinated polymer nanoplatform (PFAP) that triggers mitochondrial dysfunction to initiate pyroptosis and thereby elicits potent antitumor immunity in the lung. PFAP integrates perfluoroalkyl segments with cationic domains to enhance interactions with mitochondrial membranes, while a detachable polyethylene glycol shell preserves nanoparticle stability during aerosolization and facilitates penetration of pulmonary barriers. Upon exposure to the acidic TME, PFAP restores membrane-disruptive activity, leading to mitochondrial depolarization, Cyto C release, caspase-3 activation, GSDME cleavage, and pyroptosis induction. In orthotopic and metastatic lung cancer models, inhaled PFAP achieves efficient lung delivery, elicits robust antitumor immunity, and suppresses tumor progression without detectable systemic toxicity. This work","# Constraints
The question you must answer is from a science domain. You are a senior biomedical researcher and oncology specialist in your late 40s, based at a leading cancer research institute. You possess deep expertise in nanomedicine, tumor microenvironments, and immunotherapy mechanisms. Your career focuses on translating complex molecular findings into clinical applications, making you ideal for synthesizing technical abstracts. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,The therapeutic approach for oligometastatic non-small cell lung cancer (NSCLC) is rapidly shifting from palliative care to curative-intent strategies.,"Summarize the main finding of the biomedical study provided below in exactly one sentence.

**Study Content:**
Title: Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review. | Abstract: The therapeutic approach for oligometastatic non-small cell lung cancer (NSCLC) is rapidly shifting from palliative care to curative-intent strategies. This shift is largely driven by the integration of immune checkpoint inhibitors (ICIs) and stereotactic body radiation therapy (SBRT). SBRT functions biologically as an ""in situ vaccine,"" inducing immunogenic cell death and activating the cGAS-STING pathway to enhance systemic anti-tumor immunity, whereas ICIs may help sustain this radiation-primed immune response. Randomized phase II trials and pooled analyses have suggested the potential clinical benefit of adding radiation to ICIs, particularly in tumors with low or absent PD-L1 expression. However, the phase II/III NRG-LU002 trial found no improvement in progression-free or overall survival with the addition of local consolidative therapy to maintenance systemic therapy, indicating that the incremental benefit of local therapy may be limited in patients already deriving effective disease control from contemporary systemic regimens. Retrospective studies, including those utilizing recursive partitioning analysis and PD-L1-based stratification, have proposed a ""risk-based"" approach in which patients with an intermediate metastatic burden and low PD-L1 expression may derive greater benefit; these observations remain hypothesis-generating and require prospective validation. Look","Although combining stereotactic body radiation therapy (SBRT) with immune checkpoint inhibitors offers a compelling biological rationale for treating oligometastatic non-small cell lung cancer—particularly in patients with low PD-L1 expression—the NRG-LU002 trial suggests limited incremental survival benefit over systemic therapy alone, highlighting the need for prospective validation of a risk-stratified approach to identify subgroups that may derive clinical advantage.","Alright, let me carefully read through this study abstract to identify the main finding.

The title tells me this is a narrative review about combining SBRT with immune checkpoint inhibitors for oligometastatic NSCLC. So this isn't a single trial—it's a synthesis of multiple studies.

Let me trace through the abstract's logic:

1. The field is shifting from palliative to curative-intent for oligometastatic NSCLC, driven by SBRT + ICIs.
2. Biological rationale: SBRT acts as an ""in situ vaccine"" via immunogenic cell death and cGAS-STING activation; ICIs sustain this response.
3. Phase II trials suggested benefit of adding radiation to ICIs, especially in low/absent PD-L1 tumors.
4. BUT—the phase II/III NRG-LU002 trial found NO improvement in PFS or OS when adding local consolidative therapy to maintenance systemic therapy.
5. Retrospective studies suggest a ""risk-based"" approach—intermediate metastatic burden + low PD-L1 may benefit more, but this is hypothesis-generating.

So what's the main finding here? The abstract is presenting a tension: there's strong biological rationale and some early-phase evidence for combining SBRT with ICIs, but the more definitive NRG-LU002 trial showed limited incremental benefit. The field is now moving toward identifying which subgroups might benefit through risk stratification.

The key message seems to be: Despite the biological rationale for combining SBRT with ICIs in oligometastatic NSCLC, the NRG-LU002 trial showed limited survival benefit over systemic therapy alone, suggesting that a risk-stratified approach—particularly targeting patients with low PD-L1 expression and intermediate metastatic burden—needs prospective validation to identify who truly benefits.

Let me refine this into one clear, comprehensive sentence that captures the nuance:

Although combining stereotactic body radiation therapy (SBRT) with immune checkpoint inhibitors offers a compelling biological rationale for treating oligometastatic non-small cell lung cancer—particularly in patients with low PD-L1 expression—the NRG-LU002 trial suggests limited incremental survival benefit over systemic therapy alone, highlighting the need for prospective validation of a risk-stratified approach to identify subgroups that may derive clinical advantage.

That captures the biological rationale, the key negative trial finding, and the forward-looking risk-stratified approach. Good.","Title: Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review. | Abstract: The therapeutic approach for oligometastatic non-small cell lung cancer (NSCLC) is rapidly shifting from palliative care to curative-intent strategies. This shift is largely driven by the integration of immune checkpoint inhibitors (ICIs) and stereotactic body radiation therapy (SBRT). SBRT functions biologically as an ""in situ vaccine,"" inducing immunogenic cell death and activating the cGAS-STING pathway to enhance systemic anti-tumor immunity, whereas ICIs may help sustain this radiation-primed immune response. Randomized phase II trials and pooled analyses have suggested the potential clinical benefit of adding radiation to ICIs, particularly in tumors with low or absent PD-L1 expression. However, the phase II/III NRG-LU002 trial found no improvement in progression-free or overall survival with the addition of local consolidative therapy to maintenance systemic therapy, indicating that the incremental benefit of local therapy may be limited in patients already deriving effective disease control from contemporary systemic regimens. Retrospective studies, including those utilizing recursive partitioning analysis and PD-L1-based stratification, have proposed a ""risk-based"" approach in which patients with an intermediate metastatic burden and low PD-L1 expression may derive greater benefit; these observations remain hypothesis-generating and require prospective validation. Look","Title: Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review. | Abstract: The therapeutic approach for oligometastatic non-small cell lung cancer (NSCLC) is rapidly shifting from palliative care to curative-intent strategies. This shift is largely driven by the integration of immune checkpoint inhibitors (ICIs) and stereotactic body radiation therapy (SBRT). SBRT functions biologically as an ""in situ vaccine,"" inducing immunogenic cell death and activating the cGAS-STING pathway to enhance systemic anti-tumor immunity, whereas ICIs may help sustain this radiation-primed immune response. Randomized phase II trials and pooled analyses have suggested the potential clinical benefit of adding radiation to ICIs, particularly in tumors with low or absent PD-L1 expression. However, the phase II/III NRG-LU002 trial found no improvement in progression-free or overall survival with the addition of local consolidative therapy to maintenance systemic therapy, indicating that the incremental benefit of local therapy may be limited in patients already deriving effective disease control from contemporary systemic regimens. Retrospective studies, including those utilizing recursive partitioning analysis and PD-L1-based stratification, have proposed a ""risk-based"" approach in which patients with an intermediate metastatic burden and low PD-L1 expression may derive greater benefit; these observations remain hypothesis-generating and require prospective validation. Look","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and translational researcher specializing in thoracic malignancies, currently leading clinical trials on SBRT and immunotherapy combinations. With 15 years of experience in academic medicine, you possess deep expertise in interpreting complex biomedical literature for clinical application. Your precise understanding of NSCLC treatment paradigms makes you the ideal expert to synthesize these findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | Head and Neck Neoplasms | Immunotherapy | Squamous Cell Carcinoma of Head and Neck | Immune Checkpoint Inhibitors | Neoadjuvant Therapy | Antibodies, Monoclonal, Humanized | Perioperative Care","Identify and list the Medical Subject Headings (MeSH) terms that index the study described below. MeSH terms are a controlled vocabulary thesaurus used by the National Library of Medicine (NLM) to index articles in PubMed.

**Study Content:**
Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event-free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperati","Based on the study content provided, the following Medical Subject Headings (MeSH) terms would be used to index this article:

**Major Topics (Primary Focus)**
*   Head and Neck Neoplasms
*   Carcinoma, Squamous Cell
*   Immunotherapy
*   Immune Checkpoint Inhibitors
*   Adjuvant Therapy
*   Neoadjuvant Therapy

**Specific Agents**
*   Nivolumab
*   Pembrolizumab

**Study Design and Methodology**
*   Humans
*   Perioperative Care
*   Clinical Trials, Phase III as Topic
*   Disease-Free Survival
*   Treatment Outcome
*   Survival Analysis
*   Neoplasm Staging","Okay, I need to identify the MeSH terms for this study. Let me break down what we're working with here.

The title is ""Perioperative immunotherapy in head and neck squamous cell carcinoma"" — so right away I'm seeing several core concepts: perioperative, immunotherapy, head and neck, squamous cell carcinoma.

Now looking at the abstract... outcomes for resectable HNSCC remain suboptimal despite multimodal therapy, high recurrence rates, toxicity. Immune checkpoint inhibitors have transformed recurrent/metastatic disease management and are being advanced into perioperative and adjuvant settings. Phase III trials — adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, perioperative pembrolizumab prolonged event-free survival in resectable locally advanced HNSCCs.

So let me think about how NLM indexers would approach this. MeSH indexing follows specific principles — you identify the central concepts, check for specific drug terms, and capture methodology elements.

**Major topics first:**
- ""Head and Neck Neoplasms"" — this is the standard MeSH term for head and neck cancer
- ""Carcinoma, Squamous Cell"" — the specific histology mentioned
- ""Immunotherapy"" — this is clearly a major focus given it's in the title
- ""Immune Checkpoint Inhibitors"" — the abstract explicitly discusses these
- ""Adjuvant Therapy"" — the abstract mentions adjuvant settings and adjuvant nivolumab
- ""Neoadjuvant Therapy"" — perioperative implies both neoadjuvant and adjuvant components

**Specific agents:**
- ""Nivolumab"" — has its own MeSH heading
- ""Pembrolizumab"" — also has its own MeSH heading

**Study design and methodology elements:**
- ""Humans"" — standard check tag for clinical trials
- ""Perioperative Care"" — captures the perioperative concept
- ""Clinical Trials, Phase III as Topic"" — the abstract explicitly mentions phase III trials
- ""Disease-Free Survival"" — mentioned as an endpoint
- ""Treatment Outcome"" — general outcome measure concept
- ""Survival Analysis"" — relates to the survival endpoints discussed
- ""Neoplasm Staging"" — mentions ""pathologic high-risk"" and ""locally advanced"" which involves staging

Let me double-check this... The abstract discusses ""pathologic high-risk resected"" and ""locally advanced"" — these relate to staging, so Neoplasm Staging fits. Event-free survival and disease-free survival are both survival endpoints, so Disease-Free Survival and Survival Analysis both apply.

I think this covers the major conceptual areas. Let me organize this clearly for the response.","Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event-free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperati","Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease-free survival in pathologic high-risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event-free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperati","# Constraints
The question you must answer is from a medical domain. You are a senior medical librarian and oncology researcher with 20 years of experience indexing clinical trials. You specialize in head and neck cancers and immunotherapy, possessing deep expertise in MeSH terminology and PubMed metadata standards to accurately classify complex perioperative study data. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | Neoplasms | Immunotherapy, Adoptive | Receptors, Chimeric Antigen | Receptors, Antigen, T-Cell | T-Lymphocytes | Clinical Trials as Topic","Identify and list the Medical Subject Headings (MeSH) terms that would appropriately index the study described below. Note: MeSH is a controlled vocabulary thesaurus used for indexing articles in PubMed.

### Study Content
**Title:** Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting.
**Abstract:** Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor ef","Based on the provided title and abstract, the following Medical Subject Headings (MeSH) terms are appropriate for indexing this study:

**Primary Terms:**
*   **Immunotherapy, Adoptive** (Covers adoptive cellular therapies/ACT)
*   **Receptors, Chimeric Antigen** (Covers CAR-T therapy)
*   **Receptors, Antigen, T-Cell** (Covers TCR-T therapy)
*   **T-Lymphocytes** (The cellular vehicle for both therapies)
*   **Neoplasms** (The general term for solid tumors)

**Secondary/Supporting Terms:**
*   **Tumor Microenvironment** (Explicitly mentioned as a limiting factor)
*   **Antigens, Neoplasm** (Covers tumor-associated surface and intracellular antigens)
*   **Histocompatibility Antigens** (Covers the mention of HLA and MHC molecules)
*   **Genetic Engineering** (Relates to the engineering of T-cell receptors)
*   **Clinical Trials as Topic** (Appropriate for study updates from a major conference)
*   **Congress** (Appropriate for content derived from the ASCO Annual Meeting)","Okay, I need to identify MeSH terms for this study. Let me break down what we're working with here.

The study is about CAR-T and TCR-T therapy in solid tumors, with updates from the 2026 ASCO Annual Meeting. The abstract covers adoptive cellular therapies, the distinction between CAR-T (HLA-independent, surface antigens) and TCR-T (MHC-dependent, intracellular antigens), and challenges like antigen heterogeneity, immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns.

Let me think about the primary MeSH terms first. The overarching concept here is adoptive cellular therapy — in MeSH, that maps to ""Immunotherapy, Adoptive."" That's clearly the anchor term.

For CAR-T specifically, MeSH has ""Receptors, Chimeric Antigen"" — that's the standard heading for CAR-T work. And for TCR-T, the corresponding term would be ""Receptors, Antigen, T-Cell"" since TCR-T involves engineering the T-cell receptor. Good, those are both core.

The cellular vehicle here is T cells, so ""T-Lymphocytes"" is definitely needed. And the disease context is solid tumors — MeSH doesn't have a specific ""solid tumors"" heading, so ""Neoplasms"" is the appropriate broader term. I could consider more specific neoplasm terms, but since the abstract doesn't specify particular cancer types, ""Neoplasms"" is the right level of granularity.

Now for secondary terms. The abstract explicitly mentions the tumor microenvironment as a limiting factor, and MeSH has ""Tumor Microenvironment"" as a heading — straightforward mapping there.

Antigens are discussed in two contexts: tumor-associated surface antigens and intracellular tumor antigens. ""Antigens, Neoplasm"" covers the tumor antigen concept broadly. The HLA/MHC mention maps to ""Histocompatibility Antigens."" Both are appropriate supporting terms.

The engineering aspect — both CAR-T and TCR-T involve genetic engineering of T cells. ""Genetic Engineering"" is a valid MeSH term and captures that manufacturing/engineering concept.

Since this is derived from a conference (ASCO Annual Meeting), I should include terms reflecting that. ""Clinical Trials as Topic"" is appropriate since these are therapy updates likely involving trial data. And ""Congress"" is the standard MeSH term for conference proceedings or meeting-derived content — that's important for indexing conference abstracts.

Let me also consider whether I'm missing anything. ""Antibody Specificity"" or ""Antigen-Antibody Reactions""? No, those aren't quite right — the focus isn't on antibody-antigen interactions per se. ""Immunosuppression"" could be considered given the immunosuppressive microenvironment mention, but ""Tumor Microenvironment"" already captures that context adequately. ""Drug-Related Side Effects and Adverse Reactions"" for the safety concerns? That might be over-indexing since safety is mentioned as a challenge but isn't the primary focus. I think the terms I've selected are the most precise and appropriate set.

Let me organize these into primary and secondary categories for clarity. Primary terms are the core concepts the study is fundamentally about; secondary terms are supporting concepts that provide context and improve discoverability.Okay, let me work through this abstract carefully and map it to appropriate MeSH terms.

The study is about CAR-T and TCR-T therapies being applied to solid tumors, with updates from the 2026 ASCO Annual Meeting. Let me break down the key concepts and find the corresponding MeSH headings.

First, the overarching therapeutic modality: adoptive cellular therapies (ACT). In MeSH, this maps directly to ""Immunotherapy, Adoptive."" That's a clear primary term.

Now, the two specific therapy types:
- CAR-T therapy — chimeric antigen receptor T-cell therapy. The MeSH heading for the receptor construct itself is ""Receptors, Chimeric Antigen."" That's the standard indexing term for CAR-T work.
- TCR-T therapy — T-cell receptor-engineered T-cell therapy. The relevant MeSH heading here would be ""Receptors, Antigen, T-Cell,"" which covers T-cell receptor constructs.

The cellular vehicle for both approaches is T cells, so ""T-Lymphocytes"" should be included. That's straightforward.

The disease context: solid tumors. MeSH doesn't have a specific ""solid tumors"" heading as such — the appropriate broader term is ""Neoplasms."" Since the abstract doesn't specify particular cancer types, staying at the general ""Neoplasms"" level is the right call.

Now for secondary or supporting terms. Let me look at what else is explicitly mentioned or strongly implied:

The tumor microenvironment is directly named as a limiting factor. MeSH has ""Tumor Microenvironment"" as a heading — that's a clean mapping.

Antigens are discussed in two contexts: tumor-associated surface antigens (for CAR-T) and intracellular tumor antigens (for TCR-T). ""Antigens, Neoplasm"" captures the tumor antigen concept well.

The abstract mentions HLA and MHC molecules in the context of TCR-T recognition. ""Histocompatibility Antigens"" is the appropriate MeSH term for this.

Both CAR-T and TCR-T involve engineering T cells — there's a genetic engineering component. ""Genetic Engineering"" is a valid MeSH heading and applies here.

Since this is derived from the ASCO Annual Meeting — a major conference — I should include terms reflecting that nature. ""Clinical Trials as Topic"" is appropriate since these are therapy updates likely involving clinical trial data. And ""Congress"" is the standard MeSH term used for indexing meeting proceedings, conference abstracts, and similar content. That's important for proper indexing of conference-derived material.

Let me also consider whether I'm missing anything. ""Immunosuppression"" could be relevant given the immunosuppressive microenvironment mention, but ""Tumor Microenvironment"" already captures that context adequately. ""Antibody Specificity"" or ""Antigen-Antibody Reactions""? No, those aren't quite the right fit — the focus isn't on antibody-antigen interactions per se. Safety concerns are mentioned but are a general challenge rather than the study's primary focus, so I won't add an adverse effects term. I think the set I've identified is comprehensive and precise.

Let me organize these into primary and secondary categories for clarity.

Based on the provided title and abstract, the following Medical Subject Headings (MeSH) terms are appropriate for indexing this study:

**Primary Terms:**
*   **Immunotherapy, Adoptive** (Covers adoptive cellular therapies/ACT)
*   **Receptors, Chimeric Antigen** (Covers CAR-T therapy)
*   **Receptors, Antigen, T-Cell** (Covers TCR-T therapy)
*   **T-Lymphocytes** (The cellular vehicle for both therapies)
*   **Neoplasms** (The general term for solid tumors)

**Secondary/Supporting Terms:**
*   **Tumor Microenvironment** (Explicitly mentioned as a limiting factor)
*   **Antigens, Neoplasm** (Covers tumor-associated surface and intracellular antigens)
*   **Histocompatibility Antigens** (Covers the mention of HLA and MHC molecules)
*   **Genetic Engineering** (Relates to the engineering of T-cell receptors)
*   **Clinical Trials as Topic** (Appropriate for study updates from a major conference)
*   **Congress** (Appropriate for content derived from the ASCO Annual Meeting)","Title: Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. | Abstract: Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor ef","Title: Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. | Abstract: Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor ef","# Constraints
The question you must answer is from a medical domain. You are a senior oncology librarian and medical informatics specialist in your late 40s, based at a leading cancer research center. With two decades of experience indexing immunotherapy trials, you possess unparalleled expertise in MeSH terminology and the nuances of CAR-T and TCR-T therapies. Your meticulous attention to detail ensures precise mapping of complex abstracts to standardized medical subject headings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology.,"# Task: Biomedical Study Summary

**Objective**: Summarize the main finding of the provided biomedical study into exactly one sentence.

**Input Data**:
- **Title**: Precision before incision: neoadjuvant tumor-agnostic therapies.
- **Abstract**: The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology. Traditionally developed and approved for metastatic disease, nine therapies spanning immunotherapy, targeted agents, and antibody-drug conjugates now demonstrate a compelling rationale for earlier deployment in the neoadjuvant setting. This review examines the paradigm shift from last-resort to first-consideration approaches. Key advantages of neoadjuvant, biomarker-guided therapy include intervention prior to the development of therapeutic resistance, optimal immune system engagement, and opportunities for organ preservation. Single-agent programmed cell death protein-1 blockade has achieved a 100% complete response rate in mismatch repair-deficient rectal cancer with preserved organ function. Neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitors have demonstrated substantial responses that enable curative-intent surgery across malignancies. As precision oncology matures, the neoadjuvant tumor-agnostic approach exemplifies optimized therapeutic sequencing, potentially improving patient outcomes and quality of life.

**Constraints**:
1. **Length**: The output must be a single sentence.
2. **Focus**: Capture the core finding regarding the shift to neoadjuvant (pre-surgical) use of tumor-agnostic therapies.
3. **Tone**: Maintain a professional, scientific tone appropriate for biomedical literature.
4. **Accuracy**: Ensure the summary reflects the specific advantages mentioned (e.g., preventing resistance, organ preservation) without adding external information.","The deployment of biomarker-guided, tumor-agnostic therapies in the neoadjuvant setting represents a paradigm shift from last-resort metastatic treatment to first-consideration precision oncology, offering key advantages such as intervention prior to therapeutic resistance, organ preservation, and facilitation of curative-intent surgery that optimize therapeutic sequencing and potentially improve patient outcomes and quality of life.","Alright, I need to summarize this biomedical study into exactly one sentence. Let me break down what's being asked here.

The prompt is asking me to capture the main finding of a study about neoadjuvant tumor-agnostic therapies. Let me carefully read through the abstract to understand what this study is really about.

So the core message here is about a shift — moving tumor-agnostic therapies from their traditional use in metastatic disease (essentially last-resort scenarios) to earlier deployment in the neoadjuvant setting, which is before surgery. That's the paradigm shift they're describing: from ""last-resort"" to ""first-consideration.""

Let me identify the key elements I need to capture:

1. The core shift: neoadjuvant deployment of tumor-agnostic therapies
2. The direction of change: from metastatic/last-resort to first-consideration
3. The specific advantages mentioned:
   - Intervention before therapeutic resistance develops
   - Optimal immune system engagement
   - Organ preservation opportunities
   - Enabling curative-intent surgery (mentioned with NTRK, RET, BRAF inhibitors)
   - The impressive complete response rate with PD-1 blockade in mismatch repair-deficient rectal cancer

4. The broader implication: optimized therapeutic sequencing, potentially improving patient outcomes and quality of life

Now, the constraint says I need to capture the advantages without adding external information. I should mention things like preventing resistance and organ preservation specifically.

The tone needs to be professional and scientific — appropriate for biomedical literature. And it must be exactly ONE sentence. That's the tricky part — packing all this into a single grammatical sentence without it becoming a run-on mess.

Let me think about how to structure this. The main finding is really about the paradigm shift itself. The advantages are supporting evidence for why this shift makes sense.

Let me try drafting something:

""The deployment of biomarker-guided, tumor-agnostic therapies in the neoadjuvant setting represents a paradigm shift from last-resort metastatic treatment to first-consideration precision oncology, offering key advantages such as intervention prior to therapeutic resistance, organ preservation, and facilitation of curative-intent surgery that optimize therapeutic sequencing and potentially improve patient outcomes and quality of life.""

Let me check this against the constraints:

- Is it one sentence? Yes, it's a single complex sentence.
- Does it capture the core finding about the shift to neoadjuvant use? Yes — ""paradigm shift from last-resort metastatic treatment to first-consideration precision oncology.""
- Is the tone professional and scientific? I think so — terms like ""biomarker-guided,"" ""therapeutic sequencing,"" ""curative-intent surgery"" are all appropriate.
- Does it mention specific advantages without adding external information? Let me verify:
  - ""intervention prior to therapeutic resistance"" — yes, that's from the abstract
  - ""organ preservation"" — yes, mentioned
  - ""facilitation of curative-intent surgery"" — yes, the abstract mentions ""enable curative-intent surgery""
  - ""optimize therapeutic sequencing"" — yes, that's in the abstract
  - ""potentially improve patient outcomes and quality of life"" — yes, directly from the abstract

I didn't include the immune system engagement piece or the specific 100% complete response rate in rectal cancer. Should I include those? The constraint says to ensure the summary reflects the specific advantages mentioned. But adding everything would make the sentence unwieldy. I think I've captured the most prominent advantages. The immune system engagement is mentioned, but the three I included seem to be the most emphasized. And the specific clinical examples (rectal cancer, NTRK/RET/BRAF) are supporting evidence rather than the core finding themselves.

Actually, let me reconsider whether I should include immune system engagement. The abstract lists it as one of the ""key advantages."" Let me see if I can incorporate it naturally...

I could say ""intervention prior to therapeutic resistance, optimal immune system engagement, organ preservation, and facilitation of curative-intent surgery"" — but that's getting quite long. The sentence is already dense. I think the three advantages I've included are sufficient to represent the findings without making the sentence unreadable. The constraint says to reflect the advantages ""e.g., preventing resistance, organ preservation"" — those are the examples given, and I've covered both of those plus the surgery facilitation.

I think my draft is solid. Let me read it one more time for flow and grammar:

""The deployment of biomarker-guided, tumor-agnostic therapies in the neoadjuvant setting represents a paradigm shift from last-resort metastatic treatment to first-consideration precision oncology, offering key advantages such as intervention prior to therapeutic resistance, organ preservation, and facilitation of curative-intent surgery that optimize therapeutic sequencing and potentially improve patient outcomes and quality of life.""

The grammar checks out — ""deployment... represents"" is the main clause, ""offering"" is a participial phrase modifying the main subject, and ""that optimize"" correctly refers back to the advantages listed. The sentence flows logically from the shift, to the advantages, to the ultimate goal.

I'm satisfied with this summary. It captures the essence of the study in one sentence, maintains scientific tone, and includes the key advantages without introducing external information.

The deployment of biomarker-guided, tumor-agnostic therapies in the neoadjuvant setting represents a paradigm shift from last-resort metastatic treatment to first-consideration precision oncology, offering key advantages such as intervention prior to therapeutic resistance, organ preservation, and facilitation of curative-intent surgery that optimize therapeutic sequencing and potentially improve patient outcomes and quality of life.","Title: Precision before incision: neoadjuvant tumor-agnostic therapies. | Abstract: The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology. Traditionally developed and approved for metastatic disease, nine therapies spanning immunotherapy, targeted agents, and antibody-drug conjugates now demonstrate a compelling rationale for earlier deployment in the neoadjuvant setting. This review examines the paradigm shift from last-resort to first-consideration approaches. Key advantages of neoadjuvant, biomarker-guided therapy include intervention prior to the development of therapeutic resistance, optimal immune system engagement, and opportunities for organ preservation. Single-agent programmed cell death protein-1 blockade has achieved a 100% complete response rate in mismatch repair-deficient rectal cancer with preserved organ function. Neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitors have demonstrated substantial responses that enable curative-intent surgery across malignancies. As precision oncology matures, the neoadjuvant tumor-agnostic approach exemplifies optimized therapeutic sequencing, potentially improving patient outcomes and quality of life.","Title: Precision before incision: neoadjuvant tumor-agnostic therapies. | Abstract: The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology. Traditionally developed and approved for metastatic disease, nine therapies spanning immunotherapy, targeted agents, and antibody-drug conjugates now demonstrate a compelling rationale for earlier deployment in the neoadjuvant setting. This review examines the paradigm shift from last-resort to first-consideration approaches. Key advantages of neoadjuvant, biomarker-guided therapy include intervention prior to the development of therapeutic resistance, optimal immune system engagement, and opportunities for organ preservation. Single-agent programmed cell death protein-1 blockade has achieved a 100% complete response rate in mismatch repair-deficient rectal cancer with preserved organ function. Neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitors have demonstrated substantial responses that enable curative-intent surgery across malignancies. As precision oncology matures, the neoadjuvant tumor-agnostic approach exemplifies optimized therapeutic sequencing, potentially improving patient outcomes and quality of life.","# Constraints
The question you must answer is from a medical domain. You are a senior oncologist and translational researcher specializing in precision medicine and neoadjuvant therapies. With over 15 years of clinical experience and a focus on tumor-agnostic treatments, you bridge the gap between complex biomedical studies and practical patient care. Your expertise allows you to distill intricate clinical trial data into clear, actionable insights for medical professionals. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,"Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity.","### Task
Summarize the main finding of the provided biomedical study abstract in exactly one sentence.

### Input Data
**Title:** Bioengineering strategies for improving the immunogenicity of mRNA vaccines.
**Abstract:** Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distribution, and adaptive immune programming. In this review, we summarize bioengineering strategies for improving mRNA vaccine immunogenicity by coordinating antigen-expression efficiency with innate immune regulation. We compare non-replicating mRNA, self-amplifying RNA, and circular RNA in terms of expression kinetics, translational logic, safety considerations, and innate immune activation. We then discuss molecular engineering approaches that enhance stability, translation, and immune control, including optimization of cap structures, untranslated regions, poly(A) tails, nucleotide modifications, codon usage, and platform-specific designs for saRNA and circRNA. We further examine delivery s

### Constraints
- The output must be a single, grammatically complete sentence.
- Focus strictly on the primary conclusion or main finding regarding bioengineering strategies.
- Retain all technical terms (e.g., mRNA, saRNA, circRNA) as they appear in the source text, even if the text appears truncated.","This review concludes that improving mRNA vaccine immunogenicity requires bioengineering strategies that coordinate antigen-expression efficiency with innate immune regulation through the optimization of RNA architecture and molecular components across non-replicating mRNA, saRNA, and circRNA platforms.","Okay, let me break down what this abstract is actually saying. It's a review article about bioengineering strategies for mRNA vaccine immunogenicity. The title makes that clear, and the abstract is laying out the landscape.

So the abstract starts by acknowledging mRNA vaccines have been successful — rapid antigen design, scalable manufacturing, humoral and cellular immunity. That's context, not the finding. Then it says expansion into other disease areas (cardiovascular, neurodegenerative, autoimmune, metabolic) creates indication-specific requirements that uniform strategies can't address. That's the problem statement.

Then the key sentence: ""Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distribution, and adaptive immune programming."" This is important — it's saying it's not just about making more antigen, it's about the whole system of RNA design and delivery controlling immune responses.

Then: ""we summarize bioengineering strategies for improving mRNA vaccine immunogenicity by coordinating antigen-expression efficiency with innate immune regulation."" That's the core thesis right there — coordinating expression efficiency with innate immune regulation.

They compare three platforms: non-replicating mRNA, self-amplifying RNA (saRNA), and circular RNA (circRNA). They discuss molecular engineering — cap structures, UTRs, poly(A) tails, nucleotide modifications, codon usage. Then delivery systems but it's truncated.

So the main finding is essentially the review's central argument: improving immunogenicity isn't just about boosting antigen production, it requires coordinating expression efficiency with innate immune regulation through engineering of RNA architecture and molecular components, and this applies across multiple RNA platforms (non-replicating mRNA, saRNA, circRNA).

I need to capture this in one grammatically complete sentence. Let me draft something:

""This review concludes that improving mRNA vaccine immunogenicity requires bioengineering strategies that coordinate antigen-expression efficiency with innate immune regulation through the optimization of RNA architecture and molecular components across non-replicating mRNA, saRNA, and circRNA platforms.""

Let me check — is this one sentence? Yes. Does it capture the main finding? Yes — the coordination of expression efficiency with innate immune regulation, achieved through molecular engineering, across the three platforms. Does it retain technical terms? Yes — mRNA, saRNA, circRNA all appear as in the source. Is it grammatically complete? Yes, subject (""This review"") verb (""concludes that..."") with a complete subordinate clause.

I think that works well. It's precise and captures the dual nature of the finding — that you need both expression efficiency and innate immune regulation, achieved through bioengineering of RNA architecture and components, across the three platform types discussed.This review concludes that improving mRNA vaccine immunogenicity requires bioengineering strategies that coordinate antigen-expression efficiency with innate immune regulation through the optimization of RNA architecture and molecular components across non-replicating mRNA, saRNA, and circRNA platforms.","Title: Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Abstract: Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distribution, and adaptive immune programming. In this review, we summarize bioengineering strategies for improving mRNA vaccine immunogenicity by coordinating antigen-expression efficiency with innate immune regulation. We compare non-replicating mRNA, self-amplifying RNA, and circular RNA in terms of expression kinetics, translational logic, safety considerations, and innate immune activation. We then discuss molecular engineering approaches that enhance stability, translation, and immune control, including optimization of cap structures, untranslated regions, poly(A) tails, nucleotide modifications, codon usage, and platform-specific designs for saRNA and circRNA. We further examine delivery s","Title: Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Abstract: Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distribution, and adaptive immune programming. In this review, we summarize bioengineering strategies for improving mRNA vaccine immunogenicity by coordinating antigen-expression efficiency with innate immune regulation. We compare non-replicating mRNA, self-amplifying RNA, and circular RNA in terms of expression kinetics, translational logic, safety considerations, and innate immune activation. We then discuss molecular engineering approaches that enhance stability, translation, and immune control, including optimization of cap structures, untranslated regions, poly(A) tails, nucleotide modifications, codon usage, and platform-specific designs for saRNA and circRNA. We further examine delivery s","# Constraints
The question you must answer is from a science domain. You are a senior bioengineering researcher specializing in mRNA vaccine platforms, with a PhD in Immunology and 15 years of experience in nucleic acid therapeutics. Based in a leading biotech hub, you possess deep expertise in RNA architecture, delivery systems, and innate immune regulation. Your precise technical knowledge makes you the ideal expert to summarize complex biomedical findings accurately. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
List the MeSH terms that index this study.,"Humans | Stomach Neoplasms | Esophagogastric Junction | Female | Male | Claudins | Aged | Adenocarcinoma | Middle Aged | Retrospective Studies | Esophageal Neoplasms | Adult | Aged, 80 and over | Immunohistochemistry | Antineoplastic Combined Chemotherapy Protocols | Biomarkers, Tumor","Identify and list the Medical Subject Headings (MeSH) terms that would appropriately index the following study abstract. Note: MeSH is a controlled vocabulary thesaurus used for indexing articles in the life sciences.

Study Content:
Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN18.2 expression by immunohistochemistry in paired tumor samples from 155 patients with advanced GC/EGJC was retrospectively evaluated before and after systemic therapy. CLDN18.2-positive was defined as ≥75% of viable tumor cells exhibiting moderate-to-strong (2+ or 3+) membranous staining. Among all patients, 54 (34.84%) were CLDN18.2-positive. Following treatment, the proportion of CLDN18.2-positive patients increased significantly to 61 (39.35%) (p < .001). Among patients who were CLDN18.2-negative at base","Based on the provided study abstract, the following Medical Subject Headings (MeSH) terms are most appropriate for indexing:

**Primary Terms:**
*   **Stomach Neoplasms** (Covers gastric cancer)
*   **Esophageal Neoplasms** (Covers esophageal involvement)
*   **Esophagogastric Junction** (Covers the specific anatomical location)
*   **Adenocarcinoma** (The specific histological type mentioned)
*   **Claudins** (The MeSH descriptor for the protein family containing Claudin 18.2)
*   **Immunohistochemistry** (The method used to evaluate protein expression)
*   **Antineoplastic Combined Chemotherapy Protocols** (Covers the systemic therapy administered)

**Secondary/Supporting Terms:**
*   **Biomarkers, Tumor** (As CLDN18.2 is identified as a therapeutic target)
*   **Gene Expression Regulation, Neoplastic** (Relating to the dynamic changes in expression measured after therapy)
*   **Retrospective Studies** (The study design utilized)
*   **Humans** (The study population)
*   **Female**
*   **Male**
*   **Middle Aged**
*   **Aged**
*   **Aged, 80 and over**
*   **Adult**","Let me break down this abstract carefully to identify the appropriate MeSH terms.

The study is about CLDN18.2 expression dynamics in gastric and esophagogastric junction cancer after systemic therapy. Let me identify each key element.

**Disease entity:** The study focuses on gastric cancer and esophagogastric junction cancer. In MeSH, gastric cancer maps to ""Stomach Neoplasms."" The esophagogastric junction involvement means I need ""Esophageal Neoplasms"" as well, and there's actually a specific anatomical term ""Esophagogastric Junction"" that should be included since the study specifically references this location.

**Histological type:** The abstract explicitly mentions adenocarcinoma — ""gastric/esophagogastric junction adenocarcinoma."" So ""Adenocarcinoma"" is a necessary MeSH term.

**Molecular target:** CLDN18.2 is the central focus. MeSH doesn't have a specific descriptor for CLDN18.2, but ""Claudins"" is the MeSH term for the protein family. That's the correct mapping.

**Methodology:** The study uses immunohistochemistry to evaluate CLDN18.2 expression. ""Immunohistochemistry"" is a straightforward MeSH term here.

**Treatment:** The abstract mentions ""systemic therapy"" administered to patients. In MeSH, this would best be captured by ""Antineoplastic Combined Chemotherapy Protocols"" — systemic therapy in advanced cancer typically involves combination chemotherapy regimens.

**Biomarker aspect:** CLDN18.2 is described as ""a promising therapeutic target,"" so ""Biomarkers, Tumor"" is appropriate as a supporting term.

**Expression dynamics:** The study examines dynamic changes in expression before and after therapy. ""Gene Expression Regulation, Neoplastic"" captures this concept of altered expression in the neoplastic context.

**Study design:** This is clearly a retrospective study — ""retrospectively evaluated."" So ""Retrospective Studies"" is a necessary MeSH term.

**Population:** The study involves 155 patients — human subjects. ""Humans"" is required. The abstract doesn't specify sex breakdown, but gastric cancer studies typically include both sexes, so both ""Female"" and ""Male"" should be included. For age, advanced cancer patient populations typically span middle-aged through elderly, so I should include ""Middle Aged,"" ""Aged,"" ""Aged, 80 and over,"" and ""Adult"" to cover the likely age range.

Let me organize these into primary terms (directly central to the study) and secondary/supporting terms (methodological and demographic descriptors).

Primary terms: Stomach Neoplasms, Esophageal Neoplasms, Esophagogastric Junction, Adenocarcinoma, Claudins, Immunohistochemistry, Antineoplastic Combined Chemotherapy Protocols

Secondary terms: Biomarkers Tumor, Gene Expression Regulation Neoplastic, Retrospective Studies, Humans, Female, Male, Middle Aged, Aged, Aged 80 and over, Adult

That covers the disease, anatomy, histology, molecular target, methodology, treatment, study design, and population characteristics comprehensively.让我仔细分析这个摘要，以识别合适的MeSH术语。

这项研究关于全身治疗后胃和食管胃交界处癌中CLDN18.2表达的动态变化。让我识别每个关键元素。

**疾病实体：** 该研究集中于胃癌和食管胃交界处癌。在MeSH中，胃癌对应“Stomach Neoplasms”。食管胃交界处的参与意味着我也需要“Esophageal Neoplasms”，并且实际上有一个特定的解剖学术语“Esophagogastric Junction”应该包括在内，因为该研究特别提到了这个位置。

**组织学类型：** 摘要明确提到了腺癌——“gastric/esophagogastric junction adenocarcinoma.”因此，“Adenocarcinoma”是一个必要的MeSH术语。

**分子靶点：** CLDN18.2是中心焦点。MeSH没有针对CLDN18.2的特定描述符，但“Claudins”是蛋白质家族的MeSH术语。这是正确的映射。

**方法学：** 该研究使用免疫组织化学来评估CLDN18.2的表达。“Immunohistochemistry”在这里是一个直接的MeSH术语。

**治疗：** 摘要提到了给患者施用的“systemic therapy”。在MeSH中，这最好通过“Antineoplastic Combined Chemotherapy Protocols”来捕捉——晚期癌症的全身治疗通常涉及联合化疗方案。

**生物标志物方面：** CLDN18.2被描述为“a promising therapeutic target”，因此“Biomarkers, Tumor”作为一个支持性术语是合适的。

**表达动态：** 该研究检查了治疗前和治疗后的表达动态变化。“Gene Expression Regulation, Neoplastic”在肿瘤背景下捕捉了这种表达改变的概念。

**研究设计：** 这显然是一项回顾性研究——“retrospectively evaluated.”因此，“Retrospective Studies”是一个必要的MeSH术语。

**人群：** 该研究涉及155名患者——人类受试者。“Humans”是必需的。摘要没有指定性别细分，但胃癌研究通常包括两性，因此应包括“Female”和“Male”。对于年龄，晚期癌症患者人群通常跨越中年到老年，因此我应该包括“Middle Aged”、“Aged”、“Aged, 80 and over”以及“Adult”以覆盖可能的年龄范围。

让我将这些组织成主要术语（直接与研究核心相关）和次要/支持性术语（方法学和人口学描述符）。

主要术语：Stomach Neoplasms, Esophageal Neoplasms, Esophagogastric Junction, Adenocarcinoma, Claudins, Immunohistochemistry, Antineoplastic Combined Chemotherapy Protocols

次要术语：Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Retrospective Studies, Humans, Female, Male, Middle Aged, Aged, Aged, 80 and over, Adult

这全面涵盖了疾病、解剖学、组织学、分子靶点、方法学、治疗、研究设计和人群特征。","Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN18.2 expression by immunohistochemistry in paired tumor samples from 155 patients with advanced GC/EGJC was retrospectively evaluated before and after systemic therapy. CLDN18.2-positive was defined as ≥75% of viable tumor cells exhibiting moderate-to-strong (2+ or 3+) membranous staining. Among all patients, 54 (34.84%) were CLDN18.2-positive. Following treatment, the proportion of CLDN18.2-positive patients increased significantly to 61 (39.35%) (p < .001). Among patients who were CLDN18.2-negative at base","Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN18.2 expression by immunohistochemistry in paired tumor samples from 155 patients with advanced GC/EGJC was retrospectively evaluated before and after systemic therapy. CLDN18.2-positive was defined as ≥75% of viable tumor cells exhibiting moderate-to-strong (2+ or 3+) membranous staining. Among all patients, 54 (34.84%) were CLDN18.2-positive. Following treatment, the proportion of CLDN18.2-positive patients increased significantly to 61 (39.35%) (p < .001). Among patients who were CLDN18.2-negative at base","# Constraints
The question you must answer is from a medical domain. You are a senior medical librarian and oncology researcher with 20 years of experience in gastric cancer pathology. You specialize in MeSH indexing and immunohistochemical analysis of biomarkers like CLDN18.2. Your precise expertise ensures accurate retrieval of biomedical literature terms for clinical studies. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."
Summarize the main finding of this biomedical study in one sentence.,CD73 is a metabolic immune checkpoint that regulates the homeostatic balance of adenosine levels in the tumor microenvironment (TME).,"### Task
Summarize the main finding of the provided biomedical study abstract into a single, concise sentence.

### Input Data
**Title:** EBV hijacks the metabolic function of CD73 to resist the antitumor function of NK cells.
**Abstract:** CD73 is a metabolic immune checkpoint that regulates the homeostatic balance of adenosine levels in the tumor microenvironment (TME). However, the regulation of CD73 abnormal expression in Epstein-Barr virus (EBV)-associated malignancies remains unclear. In this study, we demonstrate that CD73 is upregulated in EBV-associated malignancies and is negatively correlated with the anti-tumor activity of NK cells. Mechanistically, EBV latent protein LMP2A upregulates CD73 through the PI3K/AKT signaling pathway, and the metabolic product of CD73, adenosine, negatively regulates the anti-tumor function of NK cells through multiple signaling pathways. Furthermore, targeted knockout of CD73, a small molecule inhibitor, or neutralizing antibody combined with the adoptive transfer of NK cells significantly improved the treatment efficacy for EBV-positive nasopharyngeal carcinoma (NPC). Importantly, we also found abnormal upregulation of CD73 in EBV-positive lymphoma, gastric cancer, and lung cancer. In summary, our research identifies the mechanism of immune evasion of NK cell anti-tumor function in EBV-associated malignancies through the abnormal expression of CD73, and targeting CD73 combined with the adoptive transfer of NK cells may provide a new strategy for immunotherapy of EBV-related malignancies.

### Constraints
- **Length:** Exactly one sentence.
- **Focus:** Capture the core mechanism (how EBV uses CD73) and the primary outcome (resistance to NK cells).
- **Tone:** Professional and scientific.","EBV latent protein LMP2A upregulates CD73 via the PI3K/AKT signaling pathway to increase adenosine production, thereby suppressing NK cell antitumor activity and enabling immune evasion in EBV-associated malignancies.","Alright, I need to summarize this abstract into a single sentence. Let me break down what's happening here.

The title already gives me a strong hint: EBV hijacks CD73's metabolic function to resist NK cell antitumor activity. Let me trace through the abstract to confirm the mechanism and outcome.

Key points I'm extracting:
- CD73 is a metabolic immune checkpoint that regulates adenosine levels in the TME
- CD73 is upregulated in EBV-associated malignancies
- This upregulation is negatively correlated with NK cell anti-tumor activity
- The mechanism: EBV latent protein LMP2A upregulates CD73 through PI3K/AKT signaling
- CD73's metabolic product (adenosine) suppresses NK cell anti-tumor function
- Targeting CD73 combined with NK cell adoptive transfer improves treatment
- This applies across multiple EBV-associated cancers

The constraints ask me to capture the core mechanism (how EBV uses CD73) and the primary outcome (resistance to NK cells). The therapeutic findings are secondary — they validate the mechanism but aren't the core finding themselves.

So the mechanism chain is: LMP2A → PI3K/AKT → CD73 upregulation → increased adenosine → NK cell suppression → immune evasion.

I need to compress this into one sentence. Let me think about what's essential versus supporting detail. The LMP2A-PI3K/AKT-CD73-adenosine-NK suppression chain is the heart of it. The therapeutic implications and the multiple cancer types are confirmatory but secondary.

Drafting: ""EBV latent protein LMP2A upregulates CD73 via the PI3K/AKT signaling pathway to increase adenosine production, thereby suppressing NK cell antitumor activity and enabling immune evasion in EBV-associated malignancies.""

That captures the mechanism (LMP2A → PI3K/AKT → CD73 → adenosine) and the outcome (NK cell suppression, immune evasion). It's one sentence, professional tone, and hits both required focus areas. I think this works well.","Title: EBV hijacks the metabolic function of CD73 to resist the antitumor function of NK cells. | Abstract: CD73 is a metabolic immune checkpoint that regulates the homeostatic balance of adenosine levels in the tumor microenvironment (TME). However, the regulation of CD73 abnormal expression in Epstein-Barr virus (EBV)-associated malignancies remains unclear. In this study, we demonstrate that CD73 is upregulated in EBV-associated malignancies and is negatively correlated with the anti-tumor activity of NK cells. Mechanistically, EBV latent protein LMP2A upregulates CD73 through the PI3K/AKT signaling pathway, and the metabolic product of CD73, adenosine, negatively regulates the anti-tumor function of NK cells through multiple signaling pathways. Furthermore, targeted knockout of CD73, a small molecule inhibitor, or neutralizing antibody combined with the adoptive transfer of NK cells significantly improved the treatment efficacy for EBV-positive nasopharyngeal carcinoma (NPC). Importantly, we also found abnormal upregulation of CD73 in EBV-positive lymphoma, gastric cancer, and lung cancer. In summary, our research identifies the mechanism of immune evasion of NK cell anti-tumor function in EBV-associated malignancies through the abnormal expression of CD73, and targeting CD73 combined with the adoptive transfer of NK cells may provide a new strategy for immunotherapy of EBV-related malignancies.","Title: EBV hijacks the metabolic function of CD73 to resist the antitumor function of NK cells. | Abstract: CD73 is a metabolic immune checkpoint that regulates the homeostatic balance of adenosine levels in the tumor microenvironment (TME). However, the regulation of CD73 abnormal expression in Epstein-Barr virus (EBV)-associated malignancies remains unclear. In this study, we demonstrate that CD73 is upregulated in EBV-associated malignancies and is negatively correlated with the anti-tumor activity of NK cells. Mechanistically, EBV latent protein LMP2A upregulates CD73 through the PI3K/AKT signaling pathway, and the metabolic product of CD73, adenosine, negatively regulates the anti-tumor function of NK cells through multiple signaling pathways. Furthermore, targeted knockout of CD73, a small molecule inhibitor, or neutralizing antibody combined with the adoptive transfer of NK cells significantly improved the treatment efficacy for EBV-positive nasopharyngeal carcinoma (NPC). Importantly, we also found abnormal upregulation of CD73 in EBV-positive lymphoma, gastric cancer, and lung cancer. In summary, our research identifies the mechanism of immune evasion of NK cell anti-tumor function in EBV-associated malignancies through the abnormal expression of CD73, and targeting CD73 combined with the adoptive transfer of NK cells may provide a new strategy for immunotherapy of EBV-related malignancies.","# Constraints
The question you must answer is from a science domain. You are a senior immunologist and virologist with 20 years of experience specializing in EBV-associated malignancies and NK cell metabolism. Based in a leading research hospital, you possess deep expertise in PI3K/AKT signaling pathways and CD73 checkpoint inhibitors. Your precise understanding of tumor microenvironment dynamics makes you the ideal expert to synthesize complex biomedical findings. Do not make reference to your persona, job or expertise in the response, your background should only inform the quality of the response.. Respond in the language of the user's prompt unless requested otherwise.

# Important
In your response, do not explicitly reference or reveal to the user the domain, persona constraints stated here. Instead, just use these constraints to improve the quality of the response. Ensure that your response is in the same language of the user."